CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:
21-398

ADMINISTRATIVE and CORRESPONDENCE DOCUMENTS
TIME SENSITIVE PATENT INFORMATION

DECLARATION

Pursuant to Sections 505(b) and (c) of the Federal Food Drug and Cosmetic Act (Act), and 21 C.F.R. §314.53, the undersigned declares that U.S. Patent No. 6,194,415 B1 ("the '415 patent") covers the method of use of Brimonidine Tartrate 0.2%/Timolol 0.5% ophthalmic solution. This product is the subject of this application for which approval is being sought.

[Signature]

Martin Voet
Vice President
Chief Intellectual Property Counsel
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612-1599
Telephone: 714 – 246-5894
TIME SENSITIVE PATENT INFORMATION

DECLARATION

Pursuant to Sections 505(b) and (c) of the Federal Food Drug and Cosmetic Act (Act), and 21 C.F.R. §314.53, the undersigned declares that U.S. Patent No. 6,248,741 B1 ("the '741 patent") covers the method of use of Brimonidine Tartrate 0.2%/Timolol 0.5% ophthalmic solution. This product is the subject of this application for which approval is being sought.

[Signature]

Martin Voet
Vice President
Chief Intellectual Property Counsel
Allergan, Inc.
2525 Dupont Drive
Irvine, CA 92612-1599
Telephone: 714 – 246-5894
14. CERTIFICATION FOR EXCLUSIVITY

Allergan, Inc. (the applicant) is submitting information in support of a request for three-year exclusivity per Section 505 (c)(3)(D) and 505 (j)(4)(D) of the Federal Food, Drug, and Cosmetic Act for Brimonidine Tartrate 0.2%/Timolol 0.5% Combination Product NDA. The results of the following two controlled clinical studies demonstrate that Brimonidine Tartrate 0.2%/Timolol 0.5% Combination Product is safe and efficacious for the lowering of intraocular pressure in patients with glaucoma or ocular hypertension. In the applicant’s opinion, these studies are essential to the approval of the new drug application for Brimonidine Tartrate 0.2%/Timolol 0.5% Combination Product. The applicant is the sponsor of IND 58,460 under which these clinical studies were conducted:

190342-012T
A multicenter, double-masked, randomized, parallel study of the safety and efficacy of 0.2% Brimonidine tartrate / 0.5% Timolol combination ophthalmic solution twice-daily compared with 0.5% Timolol twice-daily or ALPHAGAN® three-times daily for three months (plus 9-month, masked extension) in patients with glaucoma or ocular hypertension.

190342-013T
A multicenter, double-masked, randomized, parallel study of the safety and efficacy of 0.2% Brimonidine tartrate / 0.5% Timolol combination ophthalmic solution twice-daily compared with 0.5% Timolol twice-daily or ALPHAGAN® three-times daily for three months (plus 9-month, masked extension) in patients with glaucoma or ocular hypertension.
Allergan, Inc. (the applicant) has also submitted information in support of a request for an additional six month extension of exclusivity per Section 505A(d) of the Federal Food, Drug, and Cosmetic Act for Brimonidine Tartrate 0.2%/Timolol 0.5% Combination Product. A clinical study report was submitted to NDA 20-613 on August 14, 2001 in response to a June 25, 1999 FDA Written Request to determine if the use of the drug could have meaningful health benefits in the pediatric population. The applicant is the sponsor of IND 32,292 under which this clinical study was conducted:

190342-015
A 3-month, multicenter, randomized, double-masked, parallel comparison of the safety, efficacy, and tolerability of ALPHAGAN® TID vs. TRUSOPT® TID as adjunctive treatment to ophthalmic beta-blocker treatment in pediatric glaucoma patients.

Allergan, Inc., hereby certifies that to the best of our knowledge, the clinical investigations listed herein have not formed part of the basis of a finding of substantial evidence of effectiveness for a previously approved new drug application or supplement. Furthermore, no other drug product containing all of the same ingredients with the same conditions of approval has been previously approved for human use. The scientific literature has been thoroughly searched and in the applicant’s opinion there are no published studies or publicly available reports of clinical investigations (other than those sponsored by the applicant) to support the approval of the new drug application for Brimonidine Tartrate 0.2%/Timolol 0.5% Combination Product. The applicant is not aware of any approvals of this product for human use.

[Signature]
Peter A. Kresel, MS, MBA
Sr. Vice President, Global Regulatory Affairs
Allergan, Inc.

(Date)
**PATENT INFORMATION SUBMITTED WITH THE FILING OF AN NDA, AMENDMENT, OR SUPPLEMENT**

For Each Patent That Claims a Drug Substance (Active Ingredient), Drug Product (Formulation and Composition) and/or Method of Use

The following is provided in accordance with Section 505(b) and (c) of the Federal Food, Drug, and Cosmetic Act.

<table>
<thead>
<tr>
<th>TRADE NAME (OR PROPOSED TRADE NAME)</th>
<th>COMBIGINAN</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACTIVE INGREDIENT(S)</td>
<td>bromodine tartrate / timolol maleate</td>
</tr>
<tr>
<td>STRENGTH(S)</td>
<td>0.2% / 0.5%</td>
</tr>
<tr>
<td>DOSAGE FORM</td>
<td>ophthalmic solution</td>
</tr>
</tbody>
</table>

This patent declaration form is required to be submitted to the Food and Drug Administration (FDA) with an NDA application, amendment, or supplement as required by 21 CFR 314.53 at the address provided in 21 CFR 314.53(d)(4).

Within thirty (30) days after approval of an NDA or supplement, or within thirty (30) days of issuance of a new patent, a new patent declaration must be submitted pursuant to 21 CFR 314.53(c)(2)(ii) with all of the required information based on the approved NDA or supplement. The information submitted in the declaration form submitted upon or after approval will be the only information relied upon by FDA for listing a patent in the Orange Book.

For hand-written or typewriter versions (only) of this report: If additional space is required for any narrative answer (i.e., one that does not require a "Yes" or "No" response), please attach an additional page referencing the question number.

**FDA will not list patent information if you file an incomplete patent declaration or the patent declaration indicates the patent is not eligible for listing.**

For each patent submitted for the pending NDA, amendment, or supplement referenced above, you must submit all the information described below. If you are not submitting any patents for this pending NDA, amendment, or supplement, complete above section and sections 5 and 6.

1. GENERAL

| a. United States Patent Number | 6,194,415 |
| b. Issue Date of Patent        | 2/27/2001 |
| c. Expiration Date of Patent   | 6/28/2015 |

| d. Name of Patent Owner        | Allergan, Inc. |
| Address (of Patent Owner)      | 2525 Dupont Drive |

| City/State                     | Irvine, CA |
| ZIP Code                       | 92612 |
| FAX Number (if available)      | 714 246 4272 |
| Telephone Number               | 714 246 6088 |
| E-Mail Address (if available)  | gryziewicz_lewis@allergan.com |

| e. Name of agent or representative who resides or maintains a place of business within the United States authorized to receive notice of patent certification under section 505(b)(3) and (b)(2)(B) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 314.52 and 314.95 (if patent owner or NDA applicant/holder does not reside or have a place of business within the United States) |

| Address (of agent or representative named in e.) |
| City/State |
| ZIP Code |
| FAX Number (if available) |
| Telephone Number |
| E-Mail Address (if available) |

| f. Is the patent referenced above a patent that has been submitted previously for the approved NDA or supplement referenced above? | Yes □ No X |
| g. If the patent referenced above has been submitted previously for listing, is the expiration date a new expiration date? | Yes □ No X |
2. Drug Substance (Active Ingredient)

2.1 Does the patent claim the drug substance that is the active ingredient in the drug product described in the pending NDA, amendment, or supplement? □ Yes □ No

2.2 Does the patent claim a drug substance that is a different polymorph of the active ingredient described in the pending NDA, amendment, or supplement? □ Yes □ No

2.3 If the answer to question 2.2 is "Yes," do you certify that, as of the date of this declaration, you have test data demonstrating that a drug product containing the polymorph will perform the same as the drug product described in the NDA? The type of test data required is described in 21 CFR 314.53(b). □ Yes □ No

2.4 Specify the polymorphic form(s) claimed by the patent for which you have the test results described in 2.3.

2.5 Does the patent claim only a metabolite of the active ingredient pending in the NDA or supplement? (Complete the information in section 4 below if the patent claims a method of using the pending drug product to administer the metabolite.) □ Yes □ No

2.6 Does the patent claim only an intermediate? □ Yes □ No

2.7 If the patent referenced in 2.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.) □ Yes □ No

3. Drug Product (Composition/Formulation)

3.1 Does the patent claim the drug product, as defined in 21 CFR 314.3, in the pending NDA, amendment, or supplement? □ Yes □ No

3.2 Does the patent claim only an intermediate? □ Yes □ No

3.3 If the patent referenced in 3.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.) □ Yes □ No

4. Method of Use

Sponsors must submit the information in section 4 separately for each patent claim claiming a method of using the pending drug product for which approval is being sought. For each method of use claim referenced, provide the following information:

4.1 Does the patent claim one or more methods of use for which approval is being sought in the pending NDA, amendment, or supplement? □ Yes □ No

4.2 Patent Claim Number (as listed in the patent) Does the patent claim referenced in 4.2 claim a pending method of use for which approval is being sought in the pending NDA, amendment, or supplement? □ Yes □ No

4.2a If the answer to 4.2 is "Yes," identify with specificity the use with reference to the proposed labeling for the drug product. Use: (Submit indication or method of use information as identified specifically in the approved labeling.)

5. No Relevant Patents

For this pending NDA, amendment, or supplement, there are no relevant patents that claim the drug substance (active ingredient), drug product (formulation or composition) or method(s) of use, for which the applicant is seeking approval and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug product.
6. Declaration Certification

3.1 The undersigned declares that this is an accurate and complete submission of patent information for the NDA, amendment, or supplement pending under section 505 of the Federal Food, Drug, and Cosmetic Act. This time-sensitive patent information is submitted pursuant to 21 CFR 314.53. I attest that I am familiar with 21 CFR 314.53 and this submission complies with the requirements of the regulation. I verify under penalty of perjury that the foregoing is true and correct.

Warning: A willfully and knowingly false statement is a criminal offense under 18 U.S.C. 1001.

6.2 Authorized Signature of NDA Applicant/Holder or Patent Owner (Attorney, Agent, Representative or other Authorized Official) (Provide Information below)

<table>
<thead>
<tr>
<th>Name</th>
<th>Allergan, Inc.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Address</td>
<td>2424 Dupont Drive</td>
</tr>
<tr>
<td>City/State</td>
<td>Irvine, CA</td>
</tr>
<tr>
<td>ZIP Code</td>
<td>92612</td>
</tr>
<tr>
<td>Telephone Number</td>
<td>714 246 6088</td>
</tr>
<tr>
<td>E-Mail Address (if available)</td>
<td><a href="mailto:gryzlewicz_lewis@allergan.com">gryzlewicz_lewis@allergan.com</a></td>
</tr>
</tbody>
</table>

The public reporting burden for this collection of information has been estimated to average 9 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden or any other aspect of this collection of information, including suggestions for reducing this burden to:

Food and Drug Administration
CDER (HFD-007)
5600 Fishers Lane
Rockville, MD 20857

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.
**PATENT INFORMATION SUBMITTED WITH THE FILING OF AN NDA, AMENDMENT, OR SUPPLEMENT**

*For Each Patent That Claims a Drug Substance (Active Ingredient), Drug Product (Formulation and Composition) and/or Method of Use*

The following is provided in accordance with Section 505(b) and (c) of the Federal Food, Drug, and Cosmetic Act.

<table>
<thead>
<tr>
<th>TRADE NAME (OR PROPOSED TRADE NAME)</th>
<th>COMBIGAN</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ACTIVE INGREDIENT(S)</strong></td>
<td>brimonidine tartrate / timolol maleate</td>
</tr>
<tr>
<td><strong>STRENGTH(S)</strong></td>
<td>0.2% / 0.5%</td>
</tr>
<tr>
<td><strong>DOSAGE FORM</strong></td>
<td>ophthalmic solution</td>
</tr>
</tbody>
</table>

This patent declaration form is required to be submitted to the Food and Drug Administration (FDA) with an NDA application, amendment, or supplement as required by 21 CFR 314.53 at the address provided in 21 CFR 314.53(d)(4).

Within thirty (30) days after approval of an NDA or supplement, or within thirty (30) days of issuance of a new patent, a new patent declaration must be submitted pursuant to 21 CFR 314.53(c)(2)(ii) with all of the required information based on the approved NDA or supplement. The information submitted in the declaration form submitted upon or after approval will be the only information relied upon by FDA for listing a patent in the Orange Book.

For hand-written or typewriter versions (only) of this report: If additional space is required for any narrative answer (i.e., one that does not require a "Yes" or "No" response), please attach an additional page referencing the question number.

**FDA will not list patent information if you file an incomplete patent declaration or the patent declaration indicates the patent is not eligible for listing.**

For each patent submitted for the pending NDA, amendment, or supplement referenced above, you must submit all the information described below. If you are not submitting any patents for this pending NDA, amendment, or supplement, complete above section and sections 5 and 6.

### 1. GENERAL

| a. United States Patent Number | 6,248,741 |
| b. Issue Date of Patent | 6/19/2001 |
| c. Expiration Date of Patent | 6/28/2015 |
| d. Name of Patent Owner | Allergan, Inc. |
| Address (of Patent Owner) | 2525 Dupont Drive, Irvine, CA |
| ZIP Code | 92612 |
| FAX Number (if available) | 714 246 4272 |
| Telephone Number | 714 246 6088 |
| E-Mail Address (if available) | gryziewicz_lewis@allergan.com |

| e. Name of agent or representative who resides or maintains a place of business within the United States authorized to receive notice of patent certification under section 505(b)(3) and (g)(2)(B) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 314.52 and 314.95 (if patent owner or NDA applicant/holder does not reside or have a place of business within the United States) |
| Address (of agent or representative named in 1.e.) | |
| City/State | |
| ZIP Code | |
| FAX Number (if available) | |
| Telephone Number | |
| E-Mail Address (if available) | |

### 2. PATENT

| f. Is the patent referenced above a patent that has been submitted previously for the approved NDA or supplement referenced above? | ☑ No |
| g. If the patent referenced above has been submitted previously for listing, is the expiration date a new expiration date? | ☑ No |
For the patent referenced above, provide the following information on the drug substance, drug product and/or method of use that is the subject of the pending NDA, amendment, or supplement.

2. Drug Substance (Active Ingredient)

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 Does the patent claim the drug substance that is the active ingredient in the drug product described in the pending NDA, amendment, or supplement?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.2 Does the patent claim a drug substance that is a different polymorph of the active ingredient described in the pending NDA, amendment, or supplement?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.3 If the answer to question 2.2 is &quot;Yes,&quot; do you certify that, as of the date of this declaration, you have test data demonstrating that a drug product containing the polymorph will perform the same as the drug product described in the NDA? The type of test data required is described at 21 CFR 314.53(b).</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.4 Specify the polymorphic form(s) claimed by the patent for which you have the test results described in 2.3.</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.5 Does the patent claim only a metabolite of the active ingredient pending in the NDA or supplement?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Complete the information in section 4 below if the patent claims a pending method of using the pending drug product to administer the metabolite.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.6 Does the patent claim only an intermediate?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.7 If the patent referenced in 2.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3. Drug Product (Composition/Formulation)

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>3.1 Does the patent claim the drug product, as defined in 21 CFR 314.3, in the pending NDA, amendment, or supplement?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.2 Does the patent claim only an intermediate?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3.3 If the patent referenced in 3.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4. Method of Use

Sponsors must submit the information in section 4 separately for each patent claim claiming a method of using the pending drug product for which approval is being sought. For each method of use claim referenced, provide the following information:

<table>
<thead>
<tr>
<th>Question</th>
<th>Yes</th>
<th>No</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1 Does the patent claim one or more methods of use for which approval is being sought in the pending NDA, amendment, or supplement?</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.2 Patent Claim Number (as listed in the patent) 1,2,3,11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4.2a Does the patent claim referenced in 4.2 claim a pending method of use for which approval is being sought in the pending NDA, amendment, or supplement?</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

4.2a If the answer to 4.2 is "Yes," identify with specificity the use with reference to the proposed labeling for the drug product. (Submit indication or method of use information as identified specifically in the approved labeling.)

5. No Relevant Patents

For this pending NDA, amendment, or supplement, there are no relevant patents that claim the drug substance (active ingredient), drug product (formulation or composition) or method(s) of use, for which the applicant is seeking approval and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug product. | Yes |
6. Declaration Certification

6.1 The undersigned declares that this is an accurate and complete submission of patent information for the NDA, amendment, or supplement pending under section 505 of the Federal Food, Drug, and Cosmetic Act. This time-sensitive patent information is submitted pursuant to 21 CFR 314.53. I attest that I am familiar with 21 CFR 314.53 and this submission complies with the requirements of the regulation. I verify under penalty of perjury that the foregoing is true and correct.

Warning: A willfully and knowingly false statement is a criminal offense under 18 U.S.C. 1001.

6.2 Authorized Signature of NDA Applicant/Holder or Patent Owner (Attorney, Agent, Representative or other Authorized Official) (Provide Information below)

Name
Allergan, Inc.

Address
2424 Dupont Drive

City/State
Irvine, CA

ZIP Code
92612

Telephone Number
714 246 6088

FAX Number (if available)
714 246 4272

E-Mail Address (if available)
gryziewicz_lewis@allergan.com

Date Signed
7/26/06

NOTE: Only an NDA applicant/holder may submit this declaration directly to the FDA. A patent owner who is not the NDA applicant/holder is authorized to sign the declaration but may not submit it directly to FDA. 21 CFR 314.53(c)(4) and (d)(4).

Check applicable box and provide information below.

- [x] NDA Applicant/Holder
- [ ] NDA Applicant’s/Holder’s Attorney, Agent (Representative) or other Authorized Official
- [ ] Patent Owner
- [ ] Patent Owner’s Attorney, Agent (Representative) or Other Authorized Official

The public reporting burden for this collection of information has been estimated to average 9 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Food and Drug Administration
CDER (HFD-307)
5600 Fishers Lane
Rockville, MD 20857

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.
**Department of Health and Human Services**
**Food and Drug Administration**

**PATENT INFORMATION SUBMITTED WITH THE FILING OF AN NDA, AMENDMENT, OR SUPPLEMENT**

*For Each Patent That Claims a Drug Substance (Active Ingredient), Drug Product (Formulation and Composition) and/or Method of Use*

The following is provided in accordance with Section 505(b) and (c) of the Federal Food, Drug, and Cosmetic Act.

<table>
<thead>
<tr>
<th>TRADE NAME (OR PROPOSED TRADE NAME)</th>
<th>COMBIGAN</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>ACTIVE INGREDIENT(S)</th>
<th>STRENGTH(S)</th>
</tr>
</thead>
<tbody>
<tr>
<td>brimonidine tartrate / timolol maleate</td>
<td>0.2% / 0.5%</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>DOSAGE FORM</th>
<th>opthalmic solution</th>
</tr>
</thead>
</table>

This patent declaration form is required to be submitted to the Food and Drug Administration (FDA) with an NDA application, amendment, or supplement as required by 21 CFR 314.53 at the address provided in 21 CFR 314.53(d)(4).

Within thirty (30) days after approval of an NDA or supplement, or within thirty (30) days of issuance of a new patent, a new patent declaration must be submitted pursuant to 21 CFR 314.53(c)(2)(ii) with all of the required information based on the approved NDA or supplement. The information submitted in the declaration form submitted upon or after approval will be the only information relied upon by FDA for listing a patent in the Orange Book.

For hand-written or typewriter versions (only) of this report: If additional space is required for any narrative answer (i.e., one that does not require a "Yes" or "No" response), please attach an additional page referencing the question number.

FDA will not list patent information if you file an incomplete patent declaration or the patent declaration indicates the patent is not eligible for listing.

For each patent submitted for the pending NDA, amendment, or supplement referenced above, you must submit all the Information described below. If you are not submitting any patents for this pending NDA, amendment, or supplement, complete above section and sections 5 and 6.

### 1. GENERAL

<table>
<thead>
<tr>
<th>a. United States Patent Number</th>
<th>7,030,149</th>
</tr>
</thead>
<tbody>
<tr>
<td>c. Expiration Date of Patent</td>
<td>4/19/2022</td>
</tr>
<tr>
<td>d. Name of Patent Owner</td>
<td>Allergan, Inc.</td>
</tr>
<tr>
<td>Address (of Patent Owner)</td>
<td>2525 Dupont Drive</td>
</tr>
<tr>
<td>City/State</td>
<td>Irvine, CA</td>
</tr>
<tr>
<td>ZIP Code</td>
<td>92612</td>
</tr>
<tr>
<td>FAX Number (if available)</td>
<td>714 246 4272</td>
</tr>
<tr>
<td>Telephone Number</td>
<td>714 246 6088</td>
</tr>
<tr>
<td>E-Mail Address (if available)</td>
<td><a href="mailto:gryzielewicz_lewis@allergan.com">gryzielewicz_lewis@allergan.com</a></td>
</tr>
</tbody>
</table>

| e. Name of agent or representative who resides or maintains a place of business within the United States authorized to receive notice of patent certification under section 505(b)(3) and (g)(2)(B) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 314.52 and 314.95 (if patent owner or NDA applicant/holder does not reside or have a place of business within the United States) |
| Address (of agent or representative named in 1.e.) |
| City/State |
| ZIP Code |
| FAX Number (if available) |
| Telephone Number |
| E-Mail Address (if available) |

| f. Is the patent referenced above a patent that has been submitted previously for the approved NDA or supplement referenced above? | Yes | No |
| g. If the patent referenced above has been submitted previously for listing, is the expiration date a new expiration date? | Yes | No |
For the patent referenced above, provide the following information on the drug substance, drug product and/or method of use that is the subject of the pending NDA, amendment, or supplement.

### 2. Drug Substance (Active Ingredient)

2.1 Does the patent claim the drug substance that is the active ingredient in the drug product described in the pending NDA, amendment, or supplement?  
☐ Yes  ☒ No

2.2 Does the patent claim a drug substance that is a different polymorph of the active ingredient described in the pending NDA, amendment, or supplement?  
☐ Yes  ☒ No

2.3 If the answer to question 2.2 is "Yes," do you certify that, as of the date of this declaration, you have test data demonstrating that a drug product containing the polymorph will perform the same as the drug product described in the NDA? The type of test data required is described at 21 CFR 314.53(b).  
☐ Yes  ☒ No

2.4 Specify the polymorphic form(s) claimed by the patent for which you have the test results described in 2.3.

| 2.5 | Does the patent claim only a metabolite of the active ingredient pending in the NDA or supplement? (Complete the information in section 4 below if the patent claims a pending method of using the pending drug product to administer the metabolite.) | ☐ Yes | ☒ No |

| 2.6 | Does the patent claim only an intermediate? | ☐ Yes | ☒ No |

| 2.7 | If the patent referenced in 2.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.) | ☐ Yes | ☒ No |

### 3. Drug Product (Composition/Formulation)

3.1 Does the patent claim the drug product, as defined in 21 CFR 314.3, in the pending NDA, amendment, or supplement?  
☐ Yes  ☒ No

3.2 Does the patent claim only an intermediate?  
☐ Yes  ☒ No

3.3 If the patent referenced in 3.1 is a product-by-process patent, is the product claimed in the patent novel? (An answer is required only if the patent is a product-by-process patent.)  
☐ Yes  ☒ No

### 4. Method of Use

Sponsors must submit the information in section 4 separately for each patent claim claiming a method of using the pending drug product for which approval is being sought. For each method of use claim referenced, provide the following information:

4.1 Does the patent claim one or more methods of use for which approval is being sought in the pending NDA, amendment, or supplement?  
☐ Yes  ☒ No

4.2 Patent Claim Number (as listed in the patent)  
1-4

4.2a If the answer to 4.2 is "Yes," identify with specificity the use with reference to the proposed labeling for the drug product.  
Use: (Submit indication or method of use information as identified specifically in the approved labeling.) COMBIGAN (brimonidine tartrate 0.2% / timolol 0.5% ophthalmic solution) is indicated for reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

### 5. No Relevant Patents

For this pending NDA, amendment, or supplement, there are no relevant patents that claim the drug substance (active ingredient), drug product (formulation or composition) or method(s) of use, for which the applicant is seeking approval and with respect to which a claim of patent infringement could reasonably be asserted if a person not licensed by the owner of the patent engaged in the manufacture, use, or sale of the drug product.  
☐ Yes
6. Declaration Certification

6.1 The undersigned declares that this is an accurate and complete submission of patent information for the NDA, amendment, or supplement pending under section 505 of the Federal Food, Drug, and Cosmetic Act. This time-sensitive patent information is submitted pursuant to 21 CFR 314.53. I attest that I am familiar with 21 CFR 314.53 and this submission complies with the requirements of the regulation. I verify under penalty of perjury that the foregoing is true and correct.

Warning: A willfully and knowingly false statement is a criminal offense under 18 U.S.C. 1001.

6.2 Authorized Signature of NDA Applicant/Holder or Patent Owner (Attorney, Agent, Representative or other Authorized Official) (Provide Information below) Date Signed

[Signature]

7/26/06

NOTE: Only an NDA applicant/holder may submit this declaration directly to the FDA. A patent owner who is not the NDA applicant/holder is authorized to sign the declaration but may not submit it directly to FDA. 21 CFR 314.53(c)(4) and (d)(4).

Check applicable box and provide information below.

| ☒ NDA Applicant/Holder | ☐ NDA Applicant's/Holder's Attorney, Agent (Representative) or other Authorized Official |
| ☐ Patent Owner | ☐ Patent Owner's Attorney, Agent (Representative) or Other Authorized Official |

Name
Allergan, Inc.

Address
2424 DuPont Drive

City/State
Irvine, CA

ZIP Code
92612

Telephone Number
714 246 6088

FAX Number (if available)
714 246 4272

E-Mail Address (if available)
gryzlewicz_lewis@allergan.com

The public reporting burden for this collection of information has been estimated to average 9 hours per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to:

Food and Drug Administration
CDER (HFD-007)
5600 Fishers Lane
Rockville, MD 20857

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number.
EXCLUSIVITY SUMMARY

NDA # 21-398  SUPPL #  HFD # 520

Trade Name  COMBIGAN

Generic Name  brimonidine tartrate/timolol maleate ophthalmic solution

Applicant Name  Allergan, Inc.

Approval Date, If Known  10-26-07

PART I  IS AN EXCLUSIVITY DETERMINATION NEEDED?

1. An exclusivity determination will be made for all original applications, and all efficacy supplements. Complete PARTS II and III of this Exclusivity Summary only if you answer "yes" to one or more of the following questions about the submission.

   a) Is it a 505(b)(1), 505(b)(2) or efficacy supplement?  YES ☐  NO ☐

   If yes, what type? Specify 505(b)(1), 505(b)(2), SE1, SE2, SE3, SE4, SE5, SE6, SE7, SE8

      505(b)(2)

   c) Did it require the review of clinical data other than to support a safety claim or change in labeling related to safety? (If it required review only of bioavailability or bioequivalence data, answer "no.")

      YES ☒  NO ☐

   If your answer is "no" because you believe the study is a bioavailability study and, therefore, not eligible for exclusivity, EXPLAIN why it is a bioavailability study, including your reasons for disagreeing with any arguments made by the applicant that the study was not simply a bioavailability study.

   If it is a supplement requiring the review of clinical data but it is not an effectiveness supplement, describe the change or claim that is supported by the clinical data:
d) Did the applicant request exclusivity?  

YES ☐  NO ☒

If the answer to (d) is "yes," how many years of exclusivity did the applicant request?

e) Has pediatric exclusivity been granted for this Active Moiety?  

YES ☐  NO ☒

If the answer to the above question in YES, is this approval a result of the studies submitted in response to the Pediatric Written Request?

IF YOU HAVE ANSWERED "NO" TO ALL OF THE ABOVE QUESTIONS, GO DIRECTLY TO THE SIGNATURE BLOCKS AT THE END OF THIS DOCUMENT.

2. Is this drug product or indication a DESI upgrade?  

YES ☐  NO ☒

IF THE ANSWER TO QUESTION 2 IS "YES," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8 (even if a study was required for the upgrade).

PART II FIVE-YEAR EXCLUSIVITY FOR NEW CHEMICAL ENTITIES
(Answer either #1 or #2 as appropriate)

1. Single active ingredient product.

Has FDA previously approved under section 505 of the Act any drug product containing the same active moiety as the drug under consideration? Answer "yes" if the active moiety (including other esterified forms, salts, complexes, chelates or clathrates) has been previously approved, but this particular form of the active moiety, e.g., this particular ester or salt (including salts with hydrogen or coordination bonding) or other non-covalent derivative (such as a complex, chelate, or clathrate) has not been approved. Answer "no" if the compound requires metabolic conversion (other than deesterification of an esterified form of the drug) to produce an already approved active moiety.  

YES ☐  NO ☒

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA #(#s).
2. **Combination product.**

If the product contains more than one active moiety (as defined in Part II, #1), has FDA previously approved an application under section 505 containing any one of the active moieties in the drug product? If, for example, the combination contains one never-before-approved active moiety and one previously approved active moiety, answer "yes." (An active moiety that is marketed under an OTC monograph, but that was never approved under an NDA, is considered not previously approved.)

YES ☒ NO ☐

If "yes," identify the approved drug product(s) containing the active moiety, and, if known, the NDA # (s).

NDA# 18-086, 19-463 Timolol Maleate
NDA# 20-613 Alphagan
NDA#

IF THE ANSWER TO QUESTION 1 OR 2 UNDER PART II IS "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8. (Caution: The questions in part II of the summary should only be answered "NO" for original approvals of new molecular entities.) IF “YES,” GO TO PART III.

**PART III  THREE-YEAR EXCLUSIVITY FOR NDAs AND SUPPLEMENTS**

To qualify for three years of exclusivity, an application or supplement must contain "reports of new clinical investigations (other than bioavailability studies) essential to the approval of the application and conducted or sponsored by the applicant." This section should be completed only if the answer to PART II, Question 1 or 2 was "yes."

1. Does the application contain reports of clinical investigations? (The Agency interprets "clinical investigations" to mean investigations conducted on humans other than bioavailability studies.) If the application contains clinical investigations only by virtue of a right of reference to clinical investigations in another application, answer "yes," then skip to question 3(a). If the answer to 3(a) is "yes" for any investigation referred to in another application, do not complete remainder of
summary for that investigation.

IF "NO," GO DIRECTLY TO THE SIGNATURE BLOCKS ON PAGE 8.

2. A clinical investigation is "essential to the approval" if the Agency could not have approved the application or supplement without relying on that investigation. Thus, the investigation is not essential to the approval if 1) no clinical investigation is necessary to support the supplement or application in light of previously approved applications (i.e., information other than clinical trials, such as bioavailability data, would be sufficient to provide a basis for approval as an ANDA or 505(b)(2) application because of what is already known about a previously approved product), or 2) there are published reports of studies (other than those conducted or sponsored by the applicant) or other publicly available data that independently would have been sufficient to support approval of the application, without reference to the clinical investigation submitted in the application.

(a) In light of previously approved applications, is a clinical investigation (either conducted by the applicant or available from some other source, including the published literature) necessary to support approval of the application or supplement?

YES ☒ NO ☐

If "no," state the basis for your conclusion that a clinical trial is not necessary for approval AND GO DIRECTLY TO SIGNATURE BLOCK ON PAGE 8:

(b) Did the applicant submit a list of published studies relevant to the safety and effectiveness of this drug product and a statement that the publicly available data would not independently support approval of the application?

YES ☐ NO ☒

(1) If the answer to 2(b) is "yes," do you personally know of any reason to disagree with the applicant's conclusion? If not applicable, answer NO.

YES ☐ NO ☒

If yes, explain:

(2) If the answer to 2(b) is "no," are you aware of published studies not conducted or sponsored by the applicant or other publicly available data that could independently demonstrate the safety and effectiveness of this drug product?

YES ☐ NO ☒
(c) If the answers to (b)(1) and (b)(2) were both "no," identify the clinical investigations submitted in the application that are essential to the approval:

190342-012T: A Multicenter, Double-Masked, Randomized, Parallel Study of the Safety and Efficacy of 0.2% Brimonidine Tartrate/0.5% Timolol Combination Ophthalmic Solution Twice-daily Compared with 0.5% Timolol Twice-Daily or ALPHAGAN Three-Times-Daily for Three Months (Plus 9-Months, Masked Extension) in Patients with Glaucoma or Ocular Hypertension

190342-013T: A Multicenter, Double-Masked, Randomized, Parallel Study of the Safety and Efficacy of 0.2% Brimonidine Tartrate/0.5% Timolol Combination Ophthalmic Solution Twice-Daily Compared with 0.5% Timolol Twice-Daily or Extension) in Patients with Glaucoma or Ocular Hypertension

190342-019T: A Multi-Center, Double-masked, Randomized, Parallel, Four-Week Study of the Safety and Efficacy of 0.2% Brimonidine Tartrate/0.5% Timolol Combination Ophthalmic Solution BID Compared with Concurrent, ALPHAGAN TID and TIMOLOL BID (0.2% Brimonidine Tartrate and 0.5% TIMOLOL) Ophthalmic Solutions and ALPHAGAN (0.2% Brimonidine Tartrate) Ophthalmic Solution TID in Treatment-Naive Patients with Glaucoma or Ocular Hypertension

190342-023T: A Multi-Center, Randomized, Double-Masked, Parallel-Group Study to Evaluate the Safety of BID (Twice-Daily) Administration of 0.2% Brimonidine Tartrate/0.5% Timolol Fixed Combination Ophthalmic Solution Compared with ALPHAGAN (0.2% Brimonidine Tartrate) TID (Three Times Daily) and 0.5% Timolol BID Given Concurrently in Healthy, Adult Subjects for Ten Day

190342-024T : A Multi-Center, Randomized, Double-Masked, Parallel-Group Study to Evaluate the Safety of BID (Twice-Daily) Administration of 0.2% Brimonidine Tartrate 0.5% Timolol Fixed Combination Ophthalmic Solution Compared with Alphagan (0.2% Brimonidine Tartrate) TID (Three Times Daily) and 0.5% Timolol BID Given Concurrently in Glaucoma or Ocular Hypertension Patients for Ten Days

Studies comparing two products with the same ingredient(s) are considered to be bioavailability studies for the purpose of this section.

3. In addition to being essential, investigations must be "new" to support exclusivity. The agency interprets "new clinical investigation" to mean an investigation that 1) has not been relied on by the agency to demonstrate the effectiveness of a previously approved drug for any indication and 2) does not duplicate the results of another investigation that was relied on by the agency to demonstrate the
effectiveness of a previously approved drug product, i.e., does not redemonstrate something the agency considers to have been demonstrated in an already approved application.

a) For each investigation identified as "essential to the approval," has the investigation been relied on by the agency to demonstrate the effectiveness of a previously approved drug product? (If the investigation was relied on only to support the safety of a previously approved drug, answer "no.")

Investigation #1  – $\Sigma$

YES □  NO X

Investigation #2

YES □  NO □

If you have answered "yes" for one or more investigations, identify each such investigation and the NDA in which each was relied upon:

b) For each investigation identified as "essential to the approval", does the investigation duplicate the results of another investigation that was relied on by the agency to support the effectiveness of a previously approved drug product?

Investigation #1  – $\Sigma$

YES □  NO X

Investigation #2

YES □  NO □

If you have answered "yes" for one or more investigation, identify the NDA in which a similar investigation was relied on:

c) If the answers to 3(a) and 3(b) are no, identify each "new" investigation in the application or supplement that is essential to the approval (i.e., the investigations listed in #2(c), less any that are not "new"):  

190342-012T: A Multicenter, Double-Masked, Randomized, Parallel Study of the Safety and Efficacy of 0.2% Brimonidine Tartrate/0.5% Timolol Combination Ophthalmic Solution Twice-daily Compared with 0.5% Timolol Twice-Daily or ALPHAGAN Three-Times-Daily for Three Months (Plus 9-Months, Masked Extension) in Patients with Glaucoma or Ocular Hypertension

190342-013T: A Multicenter, Double-Masked, Randomized, Parallel Study of the Safety and Efficacy of 0.2% Brimonidine Tartrate/0.5% Timolol Combination Ophthalmic Solution Twice-Daily Compared with 0.5% Timolol Twice-Daily or Extension) in Patients with Glaucoma or Ocular
Hypertension

190342-019T: A Multi-Center, Double-masked, Randomized, Parallel, Four-Week Study of the Safety and Efficacy of 0.2% Brimonidine Tartrate/0.5% Timolol Combination Ophthalmic Solution BID Compared with Concurrent, ALPHAGAN TID and TIMOLOL BID (0.2% Brimonidine Tartrate and 0.5% TIMOLOL) Ophthalmic Solutions and ALPHAGAN (0.2% Brimonidine Tartrate) Ophthalmic Solution TID in Treatment-Naive Patients with Glaucoma or Ocular Hypertension

190342-023T: A Multi-Center, Randomized, Double-Masked, Parallel-Group Study to Evaluate the Safety of BID (Twice-Daily) Administration of 0.2% Brimonidine Tartrate/0.5% Timolol Fixed Combination Ophthalmic Solution Compared with ALPHAGAN (0.2% Brimonidine Tartrate) TID (Three Times Daily) and 0.5% Timolol BID Given Concurrently in Healthy, Adult Subjects for Ten Days

190342-024T: A Multi-Center, Randomized, Double-Masked, Parallel-Group Study to Evaluate the Safety of BID (Twice-Daily) Administration of 0.2% Brimonidine Tartrate 0.5% Timolol Fixed Combination Ophthalmic Solution Compared with Alphagan (0.2% Brimonidine Tartrate) TID (Three Times Daily) and 0.5% Timolol BID Given Concurrently in Glaucoma or Ocular Hypertension Patients for Ten Days

4. To be eligible for exclusivity, a new investigation that is essential to approval must also have been conducted or sponsored by the applicant. An investigation was "conducted or sponsored by" the applicant if, before or during the conduct of the investigation, 1) the applicant was the sponsor of the IND named in the form FDA 1571 filed with the Agency, or 2) the applicant (or its predecessor in interest) provided substantial support for the study. Ordinarily, substantial support will mean providing 50 percent or more of the cost of the study.

   a) For each investigation identified in response to question 3(c): if the investigation was carried out under an IND, was the applicant identified on the FDA 1571 as the sponsor?

   Investigation #1
   !
   !
   IND # 58,460 YES □ ! NO □ ! Explain:

   Investigation #2
   !
   !
   IND # YES □ ! NO □ ! Explain:

(b) For each investigation not carried out under an IND or for which the applicant was not
identified as the sponsor, did the applicant certify that it or the applicant's predecessor in interest provided substantial support for the study?

Investigation #1

<table>
<thead>
<tr>
<th>YES □</th>
<th>NO □</th>
</tr>
</thead>
<tbody>
<tr>
<td>Explain:</td>
<td>Explain:</td>
</tr>
</tbody>
</table>

Investigation #2

<table>
<thead>
<tr>
<th>YES □</th>
<th>NO □</th>
</tr>
</thead>
<tbody>
<tr>
<td>Explain:</td>
<td>Explain:</td>
</tr>
</tbody>
</table>

(c) Notwithstanding an answer of "yes" to (a) or (b), are there other reasons to believe that the applicant should not be credited with having "conducted or sponsored" the study? (Purchased studies may not be used as the basis for exclusivity. However, if all rights to the drug are purchased (not just studies on the drug), the applicant may be considered to have sponsored or conducted the studies sponsored or conducted by its predecessor in interest.)

| YES □ | NO □ |

If yes, explain:

Name of person completing form: Alison Rodgers
Title: Regulatory Health Project Manager
Date: 10-12-07

Name of Office/Division Director signing form: Wiley A. Chambers, M.D.
Title: Deputy Director, Division of Anti-Infective and Ophthalmology Products, Office of Antimicrobial Products
PEDIATRIC PAGE
(Complete for all filed original applications and efficacy supplements)

DA/BLA #: 21-398  Supplement Type (e.g. SE5):  Supplement Number: 

Stamp Date: May 3, 2007  PDUFA Goal Date: November 2, 2007

HFD 520  Trade and generic names/dosage form: COMBIGAN™ (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%

Applicant: Allergan, Inc.  Therapeutic Class: alpha-agonist/beta-blocker

Does this application provide for new active ingredient(s), new indication(s), new dosage form, new dosing regimen, or new route of administration? *

☐ Yes. Please proceed to the next question.
☐ No. PREA does not apply. Skip to signature block.

* SE5, SE6, and SE7 submissions may also trigger PREA. If there are questions, please contact the Rosemary Addy or Grace Carmouze.

Indication(s) previously approved (please complete this section for supplements only):

Each indication covered by current application under review must have pediatric studies: Completed, Deferred, and/or Waived.

Number of indications for this application(s): 1

Indication #1: Reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP.

Is this an orphan indication?

☐ Yes. PREA does not apply. Skip to signature block.

☐ No. Please proceed to the next question.

Is there a full waiver for this indication (check one)?

☐ Yes: Please proceed to Section A.

☐ No: Please check all that apply:  Partial Waiver  Deferred  Completed

NOTE: More than one may apply

Please proceed to Section B, Section C, and/or Section D and complete as necessary.

Section A: Fully Waived Studies

Reason(s) for full waiver:

☐ Products in this class for this indication have been studied/labeled for pediatric population
☐ Disease/condition does not exist in children
☐ Too few children with disease to study
☐ There are safety concerns
☐ Other:

If studies are fully waived, then pediatric information is complete for this indication. If there is another indication, please see Attachment A. Otherwise, this Pediatric Page is complete and should be entered into DFS.
Section B: Partially Waived Studies

Age/weight range being partially waived (fill in applicable criteria below):

Min _____ kg _____ mo. _____ yr. _____ Tanner Stage _____
Max _____ kg _____ mo. _____ yr. _____ Tanner Stage _____
Reason(s) for partial waiver:

☐ Products in this class for this indication have been studied/labeled for pediatric population
☐ Disease/condition does not exist in children
☐ Too few children with disease to study
☐ There are safety concerns
☐ Adult studies ready for approval
☐ Formulation needed
☐ Other: ________________________________

If studies are deferred, proceed to Section C. If studies are completed, proceed to Section D. Otherwise, this Pediatric Page is complete and should be entered into DFS.

Section C: Deferred Studies

Age/weight range being deferred (fill in applicable criteria below):

Min _____ kg _____ mo. _____ yr. _____ Tanner Stage _____
Max _____ kg _____ mo. _____ yr. _____ Tanner Stage _____
Reason(s) for deferral:

☐ Products in this class for this indication have been studied/labeled for pediatric population
☐ Disease/condition does not exist in children
☐ Too few children with disease to study
☐ There are safety concerns
☐ Adult studies ready for approval
☐ Formulation needed
☐ Other: ________________________________

Date studies are due (mm/dd/yy): ______________

If studies are completed, proceed to Section D. Otherwise, this Pediatric Page is complete and should be entered into DFS.

Section D: Completed Studies

Age/weight range of completed studies (fill in applicable criteria below):

Min _____ kg _____ mo. _____ yr. _____ 2 Tanner Stage _____
Max _____ kg _____ mo. _____ yr. _____ N/A Tanner Stage _____
Comments:

If there are additional indications, please proceed to Attachment A. Otherwise, this Pediatric Page is complete and should be entered into DFS.
This page was completed by:

(See appended electronic signature page)

Alison Rodgers
Regulatory Project Manager

FOR QUESTIONS ON COMPLETING THIS FORM CONTACT THE PEDIATRIC AND MATERNAL HEALTH STAFF at 301-796-0700

(Revised: 10/10/2006)
16. **Debarment Certification**

Allergan, Inc. hereby certifies that it did not and will not use in any capacity the services of any person debarred under section 306 of the Federal Food, Drug, and Cosmetic Act in connection with this application.

![Signature]

Lewis Gryziewicz, PharmD
Senior Director
Regulatory Affairs
Allergan, Inc.

6/9/06

Date
16. DEBARMENT CERTIFICATION

Allergan, Inc., hereby certifies that it did not and will not use in any capacity the services of any person debarred under section 306 of the Federal Food, Drug, and Cosmetic Act in connection with this application.

Peter A. Kresel, MS, MBA
Sr. Vice President, Global Regulatory Affairs
Allergan, Inc.

Aug 20, 2001
(Date)
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

CERTIFICATION: FINANCIAL INTERESTS AND
ARRANGEMENTS OF CLINICAL INVESTIGATORS

TO BE COMPLETED BY APPLICANT

With respect to all covered clinical studies (or specific clinical studies listed below (if appropriate)) submitted in support of this application, I certify to one of the statements below as appropriate. I understand that this certification is made in compliance with 21 CFR part 54 and that for the purposes of this statement, a clinical investigator includes the spouse and each dependent child of the investigator as defined in 21 CFR 54.2(c).

☐ (1) As the sponsor of the submitted studies, I certify that I have not entered into any financial arrangement with the listed clinical investigators (enter names of clinical investigators below or attach list of names to this form) whereby the value of compensation to the investigator could be affected by the outcome of the study as defined in 21 CFR 54.2(a). I also certify that each listed clinical investigator required to disclose to the sponsor whether the investigator had a proprietary interest in this product or a significant equity in the sponsor as defined in 21 CFR 54.2(b) did not disclose any such interests. I further certify that no listed investigator was the recipient of significant payments of other sorts as defined in 21 CFR 54.2(f).

☐ (2) As the applicant who is submitting a study or studies sponsored by a firm or party other than the applicant, I certify that based on information obtained from the sponsor or from participating clinical investigators, the listed clinical investigators (attach list of names to this form) did not participate in any financial arrangement with the sponsor of a covered study whereby the value of compensation to the investigator for conducting the study could be affected by the outcome of the study (as defined in 21 CFR 54.2(a)); had no proprietary interest in the product or significant equity interest in the sponsor of the covered study (as defined in 21 CFR 54.2(b)); and was not the recipient of significant payments of other sorts (as defined in 21 CFR 54.2(f)).

☐ (3) As the applicant who is submitting a study or studies sponsored by a firm or party other than the applicant, I certify that I have acted with due diligence to obtain from the listed clinical investigators (attach list of names) or from the sponsor the information required under 54.4 and it was not possible to do so. The reason why this information could not be obtained is attached.

NAME
Jeff Edwards

TITLE
Executive Vice President, Finance and Business Development, Chief Financial Officer

FIRM / ORGANIZATION
Allergan, Inc.

SIGNATURE

DATE
6-13-06

Paperwork Reduction Act Statement
An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 1 hour per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to the address to the right:

Department of Health and Human Services
Food and Drug Administration
5600 Fisher Lane, Room 14C-03
Rockville, MD 20857

FORM FDA 3454 (4/06)

financial.pdf
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

DISCLOSURE: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS

TO BE COMPLETED BY APPLICANT

The following information concerning ____________________________________________, who participated as a clinical investigator in the submitted study ____________________________________________, is submitted in accordance with 21 CFR part 54. The named individual has participated in financial arrangements or holds financial interests that are required to be disclosed as follows:

Please mark the applicable checkboxes.

☐ any financial arrangement entered into between the sponsor of the covered study and the clinical investigator involved in the conduct of the covered study, whereby the value of the compensation to the clinical investigator for conducting the study could be influenced by the outcome of the study;

☒ any significant payments of other sorts made on or after February 2, 1999 from the sponsor of the covered study such as a grant to fund ongoing research, compensation in the form of equipment, retainer for ongoing consultation, or honoraria;

☐ any proprietary interest in the product tested in the covered study held by the clinical investigator;

☐ any significant equity interest as defined in 21 CFR 54.2(b), held by the clinical investigator in the sponsor of the covered study.

Details of the individual’s disclosable financial arrangements and interests are attached, along with a description of steps taken to minimize the potential bias of clinical study results by any of the disclosed arrangements or interests.

<table>
<thead>
<tr>
<th>NAME</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jeff Edwards</td>
<td>Executive Vice President, Finance and Business Development, Chief Financial Officer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FIRM/ORGANIZATION</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergan, Inc.</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SIGNATURE</th>
<th>DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>6-13-05</td>
</tr>
</tbody>
</table>

---

Paperwork Reduction Act Statement

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 4 hours per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to:

Department of Health and Human Services
Food and Drug Administration
5600 Fishers Lane, Room 14-72
Rockville, MD 20857
Page(s) Withheld

Trade Secret / Confidential

Draft Labeling

Deliberative Process
CERTIFICATION: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS

TO BE COMPLETED BY APPLICANT

With respect to all covered clinical studies (or specific clinical studies listed below (if appropriate)) submitted in support of this application, I certify to one of the statements below as appropriate. I understand that this certification is made in compliance with 21 CFR part 54 and that for the purposes of this statement, a clinical investigator includes the spouse and each dependent child of the investigator as defined in 21 CFR 54.2(a).

☐ (1) As the sponsor of the submitted studies, I certify that I have not entered into any financial arrangement with the listed clinical investigators (enter names of clinical investigators below or attach list of names to this form) whereby the value of compensation to the investigator could be affected by the outcome of the study as defined in 21 CFR 54.2(a). I also certify that each listed clinical investigator required to disclose to the sponsor whether the investigator had a proprietary interest in this product or a significant equity in the sponsor as defined in 21 CFR 54.2(b) did not disclose any such interests. I further certify that no listed investigator was the recipient of significant payments of other sorts as defined in 21 CFR 54.2(f).

☐ (2) As the applicant who is submitting a study or studies sponsored by a firm or party other than the applicant, I certify that based on information obtained from the sponsor or from participating clinical investigators, the listed clinical investigators (attach list of names to this form) did not participate in any financial arrangement with the sponsor of a covered study whereby the value of compensation to the investigator for conducting the study could be affected by the outcome of the study (as defined in 21 CFR 54.2(a)); had no proprietary interest in this product or significant equity interest in the sponsor of the covered study (as defined in 21 CFR 54.2(b)); and was not the recipient of significant payments of other sorts (as defined in 21 CFR 54.2(f)).

☐ (3) As the applicant who is submitting a study or studies sponsored by a firm or party other than the applicant, I certify that I have acted with due diligence to obtain from the listed clinical investigators (attach list of names) or from the sponsor the information required under 54.4 and it was not possible to do so. The reason why this information could not be obtained is attached.

NAME
Eric Brandt

FIRM/ORGANIZATION
Allergan, Inc.

TITLE
Corporate Vice President and Chief Financial Officer

SIGNATURE

DATE
8/30/07

Paperwork Reduction Act Statement
An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 1 hour per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to the address to the right.

Department of Health and Human Services
Food and Drug Administration
5600 Fishers Lane, Room 14C-03
Rockville, MD 20857
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Public Health Service
Food and Drug Administration

DISCLOSURE: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS

TO BE COMPLETED BY APPLICANT

The following information concerning ___________________________, who participated as a clinical investigator in the submitted study ___________________________, is submitted in accordance with 21 CFR part 54. The named individual has participated in financial arrangements or holds financial interests that are required to be disclosed as follows:

☐ any financial arrangement entered into between the sponsor of the covered study and the clinical investigator involved in the conduct of the covered study, whereby the value of the compensation to the clinical investigator for conducting the study could be influenced by the outcome of the study;

☐ any significant payments of other sorts made on or after February 2, 1999 from the sponsor of the covered study such as a grant to fund ongoing research, compensation in the form of equipment, retainer for ongoing consultation, or honoraria;

☐ any proprietary interest in the product tested in the covered study held by the clinical investigator;

☒ any significant equity interest as defined in 21 CFR 54.2(b), held by the clinical investigator in the sponsor of the covered study.

Details of the individual's disclosable financial arrangements and interests are attached, along with a description of steps taken to minimize the potential bias of clinical study results by any of the disclosed arrangements or interests.

NAME
Eric Brandt

TITLE
Corporate Vice President and Chief Financial Officer

FIRM/ORGANIZATION
Allergan, Inc.

SIGNATURE
[Signature]

DATE
8/30/01

Paperwork Reduction Act Statement
An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 4 hours per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to:

Department of Health and Human Services
Food and Drug Administration
5600 Fishers Lane, Room 14-72
Rockville, MD 20857

FORM FDA 3455 (7/01)
**Disclosure: Financial Interests and Arrangements of Clinical Investigators**

**To Be Completed by Applicant**

The following information concerning ____________________________, who participated as a clinical investigator in the submitted study ____________________________, is submitted in accordance with 21 CFR part 54. The named individual has participated in financial arrangements or holds financial interests that are required to be disclosed as follows:

- [ ] any financial arrangement entered into between the sponsor of the covered study and the clinical investigator involved in the conduct of the covered study, whereby the value of the compensation to the clinical investigator for conducting the study could be influenced by the outcome of the study;

- [x] any significant payments of other sorts made on or after February 2, 1999 from the sponsor of the covered study such as a grant to fund ongoing research, compensation in the form of equipment, retainer for ongoing consultation, or honoraria;

- [ ] any proprietary interest in the product tested in the covered study held by the clinical investigator;

- [ ] any significant equity interest as defined in 21 CFR 54.2(b), held by the clinical investigator in the sponsor of the covered study.

Details of the individual's disclosable financial arrangements and interests are attached, along with a description of steps taken to minimize the potential bias of clinical study results by any of the disclosed arrangements or interests.

<table>
<thead>
<tr>
<th><strong>Name</strong></th>
<th><strong>Title</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Brandt</td>
<td>Corporate Vice President and Chief Financial Officer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Firm/Organization</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergan, Inc.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Signature</strong></th>
<th><strong>Date</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>8/21/9</td>
</tr>
</tbody>
</table>

**Paperwork Reduction Act Statement**

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 4 hours per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to:

Department of Health and Human Services
Food and Drug Administration
5000 Fishers Lane, Room 14-72
Rockville, MD 20857
_____ Page(s) Withheld

_____ Trade Secret / Confidential

_____ Draft Labeling

_____ Deliberative Process

Withheld Track Number: Administrative-20
DISCLOSURE: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS

TO BE COMPLETED BY APPLICANT

The following information concerning __________________, who participated as a clinical investigator in the submitted study __________________________, is submitted in accordance with 21 CFR part 54. The named individual has participated in financial arrangements or holds financial interests that are required to be disclosed as follows:

☐ any financial arrangement entered into between the sponsor of the covered study and the clinical investigator involved in the conduct of the covered study, whereby the value of the compensation to the clinical investigator for conducting the study could be influenced by the outcome of the study;

☒ any significant payments of other sorts made on or after February 2, 1999 from the sponsor of the covered study such as a grant to fund ongoing research, compensation in the form of equipment, retainer for ongoing consultation, or honoraria;

☐ any proprietary interest in the product tested in the covered study held by the clinical investigator;

☐ any significant equity interest as defined in 21 CFR 54.2(b), held by the clinical investigator in the sponsor of the covered study.

Details of the individual's disclosable financial arrangements and interests are attached, along with a description of steps taken to minimize the potential bias of clinical study results by any of the disclosed arrangements or interests.

NAME
Eric Brandt

TITLE
Corporate Vice President and Chief Financial Officer

FIRM/ORGANIZATION
Allergan, Inc.

SIGNATURE
[Signature]

DATE
8/30/01

Paperwork Reduction Act Statement

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 4 hours per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information.

Send comments regarding this burden estimate or any other aspect of this collection of information to:

Department of Health and Human Services
Food and Drug Administration
5600 Fishers Lane, Room 14-72
Rockville, MD 20857
____ Page(s) Withheld

☐ Trade Secret / Confidential

☐ Draft Labeling

☐ Deliberative Process
DISCLOSURE: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS

TO BE COMPLETED BY APPLICANT

The following information concerning ________________, who participated as a clinical investigator in the submitted study ________________, is submitted in accordance with 21 CFR part 54. The named individual has participated in financial arrangements or holds financial interests that are required to be disclosed as follows:

☐ any financial arrangement entered into between the sponsor of the covered study and the clinical investigator involved in the conduct of the covered study, whereby the value of the compensation to the clinical investigator for conducting the study could be influenced by the outcome of the study;

☒ any significant payments of other sorts made on or after February 2, 1999 from the sponsor of the covered study such as a grant to fund ongoing research, compensation in the form of equipment, retainer for ongoing consultation, or honoraria;

☐ any proprietary interest in the product tested in the covered study held by the clinical investigator;

☐ any significant equity interest as defined in 21 CFR 54.2(b), held by the clinical investigator in the sponsor of the covered study.

Details of the individual’s disclosable financial arrangements and interests are attached, along with a description of steps taken to minimize the potential bias of clinical study results by any of the disclosed arrangements or interests.

NAME
Eric Brandt

TITLE
Corporate Vice President and Chief Financial Officer

FIRM/ORGANIZATION
Allergan, Inc.

SIGNATURE

DATE 8/20/01

Paperwork Reduction Act Statement
An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 4 hours per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to:

Department of Health and Human Services
Food and Drug Administration
5000 Fishers Lane, Room 14-72
Rockville, MD 20857
Page(s) Withheld

√ Trade Secret / Confidential

Draft Labeling

Deliberative Process
DISCLOSURE: FINANCIAL INTERESTS AND ARRANGEMENTS OF CLINICAL INVESTIGATORS

TO BE COMPLETED BY APPLICANT

The following information concerning ____________________________, who participated as a clinical investigator in the submitted study ____________________________, is submitted in accordance with 21 CFR part 54. The named individual has participated in financial arrangements or holds financial interests that are required to be disclosed as follows:

☐ any financial arrangement entered into between the sponsor of the covered study and the clinical investigator involved in the conduct of the covered study, whereby the value of the compensation to the clinical investigator for conducting the study could be influenced by the outcome of the study;

☒ any significant payments of other sorts made on or after February 2, 1999 from the sponsor of the covered study such as a grant to fund ongoing research, compensation in the form of equipment, retainer for ongoing consultation, or honoraria;

☐ any proprietary interest in the product tested in the covered study held by the clinical investigator;

☐ any significant equity interest as defined in 21 CFR 54.2(b), held by the clinical investigator in the sponsor of the covered study.

Details of the individual’s disclosable financial arrangements and interests are attached, along with a description of steps taken to minimize the potential bias of clinical study results by any of the disclosed arrangements or interests.

<table>
<thead>
<tr>
<th>NAME</th>
<th>TITLE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Brandt</td>
<td>Corporate Vice President and Chief Financial Officer</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FIRM/ORGANIZATION</th>
<th>SIGNATURE</th>
<th>DATE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Allergan, Inc.</td>
<td>[Signature]</td>
<td>8/20/07</td>
</tr>
</tbody>
</table>

Paperwork Reduction Act Statement

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. Public reporting burden for this collection of information is estimated to average 4 hours per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the necessary data, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information to:

Department of Health and Human Services
Food and Drug Administration
5600 Fishers Lane, Room 14-72
Rockville, MD 20857

FORM FDA 3455 (7/01)
____ Page(s) Withheld

✓ Trade Secret / Confidential

_____ Draft Labeling

_____ Deliberative Process
DATE: June 8, 2007

TO: File

FROM: Alison Rodgers

SUBJECT: NDA 21-398 Resubmission May 2, 2007
NDA 21-398, COMBIGAN (brimonidine tartrate/timolol maleate ophthalmic solution)

The May 2, 2007, resubmission of NDA 21-398 is acceptable from a project management standpoint.
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Alison Rodgers
6/8/2007 02:53:22 PM
CSO
Hi Lew,

Listed below is our statistician’s response to your request for clarification. I hope this helps. Please let me know if you need more information.

The programs outlined in 1. are adequate. Our intention is to reproduce the results and examine how they were created. The operating system is MS Windows 2000 with SAS Version 8.

Alison

Alison K. Rodgers
Regulatory Health Project Manager
FDA/CDER
Division of Anti-Infective and Ophthalmology Products
Phone: 301-796-0797
Fax: 301-796-9882
Email: alison.rogers@fda.hhs.gov

Alison,

In response to your request we are seeking clarification on what the FDA Statistician expects to receive for the Combigan 024T study. Could you respond to our questions listed below? If necessary we could discuss on the phone with the Statistician.

Thanks,

Lew

1. We will send the programs that create analysis data sets for the primary and secondary analyses as well as the programs that create the tables for these analyses. These tables are listed. Are these the programs that are requested?

   Current Severity of Sleepiness
   14.3-2.1 Proportion of Sleepiness Responders
   14.3-2.2 Proportion of Patients with an Increase of >=2 Units at Each Visit and Overall
   14.3-2.3 Frequency Distribution

6/6/2007
2. Is the intention for the FDA to run the programs or to look at the coding logic? Our programs have been written for the UNIX operating system.

3. If the FDA will be running the programs:
   a. What operating system will be used?
   b. What version of SAS will be used?

From: Rogers, Alison [mailto:Alison.Rodgers@fda.hhs.gov]
Sent: Tuesday, June 05, 2007 6:29 AM
To: Gryziewicz Lewis
Subject: NDA 21-398 - Request for Information

Hi Lew,

Please see below a request from our statistician. Please submit your response to the NDA. Please let me know when you plan to respond. Let me know if you have any questions.

We request that the Sponsor include SAS programs used in conducting the primary analyses, related
sensitivity analyses and secondary analyses for Study 190342-024T.

Also, I did receive your message about submitting the carton and container labeling today. That's fine.

Thanks,

Alison

Alison K. Rodgers
Regulatory Health Project Manager
FDA/CDER
Division of Anti-Infective and Ophthalmology Products
Phone: 301-796-0797
Fax: 301-796-9882
Email: alison.rogers@fda.hhs.gov

6/6/2007
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
____________________
Alison Rodgers
6/6/2007 12:58:12 PM
CSO

Alison Rodgers
6/6/2007 12:58:41 PM
CSO
NDA 21-398

Allergan, Inc.
Attention: Lewis Gryziewicz, PharmD
Senior Director, Global Regulatory Affairs
2525 Dupont Drive
P.O. Box 19534
Irvine, CA 92623-9534

Dear Dr. Gryziewicz:

We acknowledge receipt on May 3, 2007 of your May 2, 2007 resubmission to your new drug application for COMBIGAN™ (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%.

We consider this a complete, class 2 response to our December 20, 2006 action letter. Therefore, the user fee goal date is November 3, 2007.

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at (301) 796-0797.

Sincerely,

(See appended electronic signature page)

Maureen P. Dillon-Parker
Chief, Project Management Staff
Division of Anti-Infective and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Alison Rodgers
5/15/2007 02:37:52 PM

Maureen Dillon-Parker
5/16/2007 08:40:37 AM
NDA 21-398; Ack Ltr Resubmission
CLINICAL INSPECTION SUMMARY

DATE: November 14, 2006

TO: Alison Rodgers, Regulatory Project Manager
    Jennifer Harris, M.D., Clinical Reviewer
    Division of Anti-Infective and Ophthalmology Products, HFD-520

THROUGH: Leslie K. Ball, M.D.
           Branch Chief
           Good Clinical Practice Branch 2, HFD-47
           Division of Scientific Investigations

FROM: Dianne Tesch, Consumer Safety Officer

SUBJECT: Evaluation of Clinical Inspections

NDA: 21-398

NME: No

APPLICANT: Allergan, Inc.

DRUG: Combigan™ (brimonidine tartrate 0.2% / timolol 0.5%) Ophthalmic Solution

THERAPEUTIC CLASSIFICATION: 4S

INDICATION:

CONSULTATION REQUEST DATE: July 26, 2006

DIVISION ACTION GOAL DATE: 11/20/06

PDUFA DATE: 12/29/06

I. BACKGROUND:

Glaucoma refers to a group of eye diseases characterized by an increase in the intraocular pressure (IOP) which causes pathological changes in the optic disc and defects in the field of vision. It affects one person in 200 over the age of 40. It is the leading cause of irreversible blindness in the United States. Glaucoma causes a progressive loss of retinal nerve fibers, resulting in vision loss. The various types of glaucoma are distinguished by the causative physiological defect.
Treatment of glaucoma consists of both medical and surgical interventions. The treatments are designed to decrease the intra-ocular pressure by decreasing aqueous secretion, or increasing aqueous outflow.

Timolol ophthalmic solution 0.5%, a non-selective beta-blocker, and brimonidine ophthalmic solution (ALPHAGAN®) 0.2%, a selective and potent alpha-2 adrenoceptor agonist, have both been shown to effectively reduce IOP. Because timolol and brimonidine have different sites of action and different mechanisms by which they lower IOP, it is reasonable to expect that there will be an added IOP lowering effect when the 2 medications are used adjunctively.

Currently, the 2 marketed medications are often prescribed and used together, but this requires that the patient must have 2 separate bottles of medications and results in a cumbersome dosing regimen. Use of 2 separate bottles requires patients to dose 5 drops per eye per day with a 5 minute wait in-between dosing of the 2 bottles. Reducing the number of drops per eye per day may improve dosing compliance. The sponsor has combined these 2 ocular hypotensive medications into a single formulation to provide the benefit of adjunctive therapy with a more convenient dosing regimen (i.e., one drop in each eye twice daily).

Dr. McCormack’s site was chosen for inspection because of high enrollment, and because he has never been inspected.

Summary Report of U.S. Inspections

II. RESULTS (by protocol/site):

<table>
<thead>
<tr>
<th>Name of CI and site #, if known</th>
<th>City, State*</th>
<th>Protocol #</th>
<th>Insp. Date</th>
<th>EIR Received Date</th>
<th>Final Classification</th>
</tr>
</thead>
<tbody>
<tr>
<td>Donald L. McCormack</td>
<td>Boulder, CO</td>
<td>190342-023T-00</td>
<td>Oct. 10-18, 2006</td>
<td>Nov. 7, 2006</td>
<td>NAI</td>
</tr>
</tbody>
</table>

*If international site, please insert column for country.

Key to Classifications
NAI = No deviation from regulations. Data acceptable.
VAL-No Response Requested = Deviation(s) from regulations. Data acceptable.
VAL-Response Requested = Deviation(s) from regulations. See specific comments below for data acceptability.
OAI = Significant deviations for regulations. Data unreliable.

A. Protocol #190342-023T-00 “A Multi-Center, Randomized, Double-Masked, Parallel-Group Study to Evaluate the Safety of BID (Twice-Daily) Administration of 0.2% Brimonidine Tartrate / 0.5% Timolol Fixed Combination Ophthalmic Solution Compared with ALPHAGAN® (0.2% Brimonidine Tartrate) TID (Three Times Daily) and 0.5% Timolol BID Given Concurrently in Healthy, Adult Subjects for Ten Days”

1. Donald L. McCormack, Boulder, CO; site 1942:

   a. Fifty-eight subjects were enrolled in this clinical study. Forty-nine were randomized. Forty-eight subjects completed the study. One withdrew consent after experiencing an adverse event. All subject files were reviewed for compliance with eligibility requirements, informed consent, and drug accountability. Twenty-seven subjects’ records were reviewed in depth for accuracy of reporting of endpoint data.

   b. There were no limitations to the inspection.

   c. There were minor clerical errors in the record keeping. No significant regulatory deficiencies were found.
d. The study appears to have been conducted adequately, and the data generated by this site appear acceptable in support of the respective indication.

III. OVERALL ASSESSMENT OF FINDINGS AND GENERAL RECOMMENDATIONS

There were minor clerical errors at this site which did not affect the integrity or reliability of the data submitted in support of subject NDA or significant patient safety issues.

No follow-up other than routine surveillance is indicated.

{See appended electronic signature page}

Dianne Tesch, Consumer Safety Officer

CONCURRENCE:

Supervisory comments

{See appended electronic signature page}

Leslie K. Ball, M.D.
Branch Chief
Good Clinical Practice Branch II
Division of Scientific Investigations
This is a representation of an electronic record that was signed electronically and 
this page is the manifestation of the electronic signature.

/s/

Dianne Tesch
11/16/2006 09:15:39 AM
CSO

Leslie Ball
11/20/2006 08:17:50 PM
MEDICAL OFFICER
Hi Lew,

Please see CMC comments below regarding NDA 21-398. Please submit your response to the NDA, and send an electronic copy to me, if possible. Also, please let me know when you will respond.

Thank you.

NDA 21-398 COMBIGAN (Brimonidine Tartrate 0.2% / Timolol 0.5%) Ophthalmic Solution

These comments are being provided to you prior to completion of our review of the application to give you preliminary notice of issues that have been identified. Per the user fee reauthorization agreements, these comments do not reflect a final decision on the information reviewed and should not be construed to do so. These comments are preliminary and are subject to change as the review of your application is finalized. In addition, we may identify other information that must be provided prior to approval of this application. Depending on the timing of your response, as per user fee reauthorization agreements, we may or may not be able to consider your response prior to taking an action on your application during this review cycle.

If your response can be found in the contents of your submission, just cite those sections of the submission that are relevant to the issue under consideration. Otherwise, provide the appropriate information. Your response should be submitted as an amendment to the submission and a copy via facsimile to the reviewer.

CMC COMMENTS

2. If yes, please revise the "Analytical Procedure for Brimonidine Tartrate, Timolol, and Their Impurities" to include the

3. Although the formation of it is attributed to is conceivable that this is a result of a reaction of Were preformulation studies conducted to study the Please provide a study report or reference to such a study in your application.

Alison K. Rodgers
Regulatory Health Project Manager
FDA/CDER
Division of Anti-Infective and Ophthalmology Products
Phone: 301-796-0797
Fax: 301-796-9882
Email: alison.rogers@fda.hhs.gov
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Alison Rodgers
10/18/2006 02:48:27 PM
CSO

Alison Rodgers
10/18/2006 02:48:55 PM
CSO
NDA REGULATORY FILING REVIEW
(Including Memo of Filing Meeting)

NDA # 21-398  Supplement #  Efficacy Supplement Type SE-

Proprietary Name: COMBIGAN™
Established Name: brimonidine tartrate/timolol maleate ophthalmic solution
Strengths: 0.2%/0.5%

Applicant: Allergan, Inc.
Agent for Applicant (if applicable):

Date of Application: 6-29-06
Date of Receipt: 6-30-06
Date clock started after UN:
Date of Filing Meeting: 7-25-06
Filing Date: N/A (This is a resubmission.)
Action Goal Date (optional): User Fee Goal Date: 12-30-06

Indication(s) requested: Reduction of elevated intraocular pressure in patients with glaucoma or ocular hypertension

Type of Original NDA: AND (if applicable) (b)(1) X (b)(2)
Type of Supplement: (b)(1) X (b)(2)

NOTE:
(1) If you have questions about whether the application is a 505(b)(1) or 505(b)(2) application, see Appendix A. A supplement can be either a (b)(1) or a (b)(2) regardless of whether the original NDA was a (b)(1) or a (b)(2). If the application or efficacy supplement is a (b)(2), complete Appendix B.

Review Classification:
Resubmission after withdrawal? S X
Chemical Classification: (1,2,3 etc.) 4
Other (orphan, OTC, etc.)

Resubmission after refuse to file? P X

Form 3397 (User Fee Cover Sheet) submitted: YES N/A □ NO □

User Fee Status: N/A Paid □ Exempt (orphan, government) □
Waived (e.g., small business, public health) □

NOTE: If the NDA is a 505(b)(2) application, and the applicant did not pay a fee in reliance on the 505(b)(2) exemption (see box 7 on the User Fee Cover Sheet), confirm that a user fee is not required by contacting the User Fee staff in the Office of Regulatory Policy. The applicant is required to pay a user fee if: (1) the product described in the 505(b)(2) application is a new molecular entity or (2) the applicant claims a new indication for a use that has not been approved under section 505(b). Examples of a new indication for a use include a new indication, a new dosing regime, a new patient population, and an Rx-to-OTC switch. The best way to determine if the applicant is claiming a new indication for a use is to compare the applicant's proposed labeling to labeling that has already been approved for the product described in the application.

Version 6/14/2006
Highlight the differences between the proposed and approved labeling. If you need assistance in determining if the applicant is claiming a new indication for a use, please contact the User Fee staff:

- Is there any 5-year or 3-year exclusivity on this active moiety in any approved (b)(1) or (b)(2) application? YES ☐ NO ☒
  If yes, explain:

Note: If the drug under review is a 505(b)(2), this issue will be addressed in detail in appendix B.
- Does another drug have orphan drug exclusivity for the same indication? YES ☐ NO ☒

- If yes, is the drug considered to be the same drug according to the orphan drug definition of sameness [21 CFR 316.3(b)(13)]? YES ☐ NO ☐
  If yes, consult the Director, Division of Regulatory Policy II, Office of Regulatory Policy (HFD-007).

- Is the application affected by the Application Integrity Policy (AIP)? YES ☐ NO ☒
  If yes, explain:

- If yes, has OC/DMPQ been notified of the submission? YES ☐ NO ☒

- Does the submission contain an accurate comprehensive index? YES ☒ NO ☐
  If no, explain:

- Was form 356h included with an authorized signature? YES ☒ NO ☐
  If foreign applicant, both the applicant and the U.S. agent must sign.

- Submission complete as required under 21 CFR 314.50? YES ☒ NO ☐
  If no, explain:

- Answer 1, 2, or 3 below (do not include electronic content of labeling as an partial electronic submission).

1. This application is a paper NDA YES ☐

2. This application is an eNDA or combined paper + eNDA YES ☐
   This application is: All electronic ☐ Combined paper + eNDA ☒
   This application is in: NDA format ☐ CTD format ☒
   Combined NDA and CTD formats ☐

   Does the eNDA, follow the guidance? (http://www.fda.gov/cder/guidance/2353fni.pdf) YES ☒ NO ☐

   If an eNDA, all forms and certifications must be in paper and require a signature.
   If combined paper + eNDA, which parts of the application were submitted in electronic format?

   Additional comments:

3. This application is an eCTD NDA. YES ☐

Version 6/14/2006
If an eCTD NDA, all forms and certifications must either be in paper and signed or be electronically signed.

Additional comments:

- Patent information submitted on form FDA 3542a?  
  YES  X  NO  □

- Exclusivity requested?  
  YES, _____ Years  NO  X  
  NOTE: An applicant can receive exclusivity without requesting it; therefore, requesting exclusivity is not required.

- Correctly worded Debarment Certification included with authorized signature?  
  YES  X  NO  □  
  If foreign applicant, both the applicant and the U.S. Agent must sign the certification.

  NOTE: Debarment Certification should use wording in FD&C Act section 306(b)(1) i.e., “[Name of applicant] hereby certifies that it did not and will not use in any capacity the services of any person debarred under section 306 of the Federal Food, Drug, and Cosmetic Act in connection with this application.” Applicant may not use wording such as “To the best of my knowledge . . . .”

- Are the required pediatric assessment studies and/or deferral/partial waiver/full waiver of pediatric studies (or request for deferral/partial waiver/full waiver of pediatric studies) included?  
  Submitted in original NDA.  
  YES  □  NO  X

- If the submission contains a request for deferral, partial waiver, or full waiver of studies, does the application contain the certification required under FD&C Act sections 505B(a)(3)(B) and (4)(A) and (B)?  
  Submitted in original NDA.  
  YES  □  NO  X

- Is this submission a partial or complete response to a pediatric Written Request?  
  YES  □  NO  X  
  If yes, contact PMHT in the OND-IO

- Financial Disclosure forms included with authorized signature?  
  YES  X  NO  □  
  (Forms 3454 and/or 3455 must be included and must be signed by the APPLICANT, not an agent.)  
  NOTE: Financial disclosure is required for bioequivalence studies that are the basis for approval.

- Field Copy Certification (that it is a true copy of the CMC technical section)  
  YES  □  NO  X

- PDUFA and Action Goal dates correct in tracking system?  
  YES  X  NO  □  
  If not, have the document room staff correct them immediately. These are the dates EES uses for calculating inspection dates.

- Drug name and applicant name correct in COMIS?  
  If not, have the Document Room make the corrections. Ask the Doc Rm to add the established name to COMIS for the supporting IND if it is not already entered.

- List referenced IND numbers: 58,460, 32,292

- Are the trade, established/proper, and applicant names correct in COMIS?  
  YES  X  NO  □  
  If no, have the Document Room make the corrections.

- End-of-Phase 2 Meeting(s)?  
  Date(s) ___________________________  NO  X  
  If yes, distribute minutes before filing meeting.
• Pre-NDA Meeting(s)?  Date(s)   NO  X
If yes, distribute minutes before filing meeting.

• Any SPA agreements?  Date(s)  8-31-05; 11-10-05  NO
If yes, distribute letter and/or relevant minutes before filing meeting.

**Project Management**

• If Rx, was electronic Content of Labeling submitted in SPL format?  YES  X  NO  □
If no, request in 74-day letter.

• If Rx, for all new NDAs/efficacy supplements submitted on or after 6/30/06:
  Was the PI submitted in PLR format?  YES  □  NO  □
If no, explain. Was a waiver or deferral requested before the application was received or in the submission? If before, what is the status of the request: **PLR is not required since this is a resubmission following an approvable letter.**

• If Rx, all labeling (PI, PPI, MedGuide, carton and immediate container labels) has been consulted to DDMAC?  YES  X  NO  □

• If Rx, trade name (and all labeling) consulted to OSE/DMETS?  YES  X  NO  □
  • If Rx, MedGuide and/or PPI (plus PI) consulted to ODE/DSRCS?  N/A  YES  □  NO  □

• Risk Management Plan consulted to OSE/IO?  N/A  X  YES  □  NO  □

• If a drug with abuse potential, was an Abuse Liability Assessment, including a proposal for scheduling submitted?  NA  X  YES  □  NO  □

**If Rx-to-OTC Switch or OTC application: N/A**

• Proprietary name, all OTC labeling/packaging, and current approved PI consulted to OSE/DMETS?  YES  □  NO  □

• If the application was received by a clinical review division, has DNPCE been notified of the OTC switch application? Or, if received by DNPCE, has the clinical review division been notified?  YES  □  NO  □

**Clinical**

• If a controlled substance, has a consult been sent to the Controlled Substance Staff?  N/A  YES  □  NO  □

**Chemistry**  (Note: The environmental assessment was submitted in the original NDA.)

• Did applicant request categorical exclusion for environmental assessment?  YES  □  NO  X
If no, did applicant submit a complete environmental assessment?  YES  □  NO  X
If EA submitted, consulted to EA officer, OPS?  YES  □  NO  □
• Establishment Evaluation Request (EER) submitted to DMPQ? YES X NO □
• If a parenteral product, consulted to Microbiology Team? N/A YES □ NO □

ATTACHMENT

MEMO OF FILING MEETING

DATE: 7-25-06

NDA #: 21-398

DRUG NAMES: COMBIGAN™ (brimonidine tartrate/timolol maleate ophthalmic solution)

APPLICANT: Allergan, Inc.


ASSIGNED REVIEWERS (including those not present at filing meeting):

<table>
<thead>
<tr>
<th>Discipline/Organization</th>
<th>Reviewer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical:</td>
<td>William Boyd</td>
</tr>
<tr>
<td>Secondary Medical:</td>
<td>N/A</td>
</tr>
<tr>
<td>Statistical:</td>
<td>Chris Khedouri</td>
</tr>
<tr>
<td>Pharmacology:</td>
<td>Zhou Chen</td>
</tr>
<tr>
<td>Statistical Pharmacology:</td>
<td>N/A</td>
</tr>
<tr>
<td>Chemistry:</td>
<td>Lin Qi</td>
</tr>
<tr>
<td>Environmental Assessment (if needed):</td>
<td>N/A</td>
</tr>
<tr>
<td>Biopharmaceutical:</td>
<td>Bryan Riley</td>
</tr>
<tr>
<td>Microbiology, sterility:</td>
<td>N/A</td>
</tr>
<tr>
<td>Microbiology, clinical (for antimicrobial products only):</td>
<td>N/A</td>
</tr>
<tr>
<td>DSI:</td>
<td></td>
</tr>
<tr>
<td>OPS:</td>
<td>Alison Rodgers</td>
</tr>
<tr>
<td>Regulatory Project Management:</td>
<td>Sheila Ryan</td>
</tr>
<tr>
<td>Other Consults:</td>
<td></td>
</tr>
<tr>
<td>DMETS</td>
<td></td>
</tr>
<tr>
<td>DDMAC</td>
<td></td>
</tr>
</tbody>
</table>

Per reviewers, are all parts in English or English translation? YES X NO □

If no, explain:

CLINICAL FILE X REFUSE TO FILE □

• Clinical site audit(s) needed? YES □ NO X
  If no, explain:
• Advisory Committee Meeting needed? YES, date if known □ NO X

Version 6/14/2006
● If the application is affected by the AIP, has the division made a recommendation regarding whether or not an exception to the AIP should be granted to permit review based on medical necessity or public health significance? N/A X YES □ NO □

CLINICAL MICROBIOLOGY
N/A X FILE □ REFUSE TO FILE □

STATISTICS
N/A □ FILE X REFUSE TO FILE □

BIOPHARMACEUTICS
N/A □ FILE X REFUSE TO FILE □

● Biopharm. study site audits(s) needed? YES □ NO □

PHARMACOLOGY/TOX
N/A □ FILE X REFUSE TO FILE □

● GLP audit needed? YES □ NO □

CHEMISTRY
FILE X REFUSE TO FILE □

● Establishment(s) ready for inspection? YES □ NO □
● Sterile product? YES X NO □
    If yes, was microbiology consulted for validation of sterilization? YES X NO □

ELECTRONIC SUBMISSION:
Any comments:

REGULATORY CONCLUSIONS/DEFICIENCIES:
(Refer to 21 CFR 314.101(d) for filing requirements.)

□ The application is unsuitable for filing. Explain why:

X The application, on its face, appears to be well-organized and indexed. The application appears to be suitable for filing.

X No filing issues have been identified.

□ Filing issues to be communicated by Day 74. List (optional):

ACTION ITEMS:

1. □ Ensure that the review and chemical classification codes, as well as any other pertinent classification codes (e.g., orphan, OTC) are correctly entered into COMIS.

2. □ If RTF, notify everybody who already received a consult request of RTF action. Cancel the EER.

3. □ If filed and the application is under the AIP, prepare a letter either granting (for signature by Center Director) or denying (for signature by ODE Director) an exception for review.

Version 6/14/2006
4. □ If filed, complete the Pediatric Page at this time. (If paper version, enter into DFS.)

5. □ Convey document filing issues/no filing issues to applicant by Day 74.

Alison Rodgers
Regulatory Project Manager
Appendix A to NDA Regulatory Filing Review

NOTE: The term "original application" or "original NDA" as used in this appendix denotes the NDA submitted. It does not refer to the reference drug product or "reference listed drug."

An original application is likely to be a 505(b)(2) application if:

1. it relies on published literature to meet any of the approval requirements, and the applicant does not have a written right of reference to the underlying data. If published literature is cited in the NDA but is not necessary for approval, the inclusion of such literature will not, in itself, make the application a 505(b)(2) application,

2. it relies for approval on the Agency’s previous findings of safety and efficacy for a listed drug product and the applicant does not own or have right to reference the data supporting that approval, or

3. it relies on what is "generally known” or "scientifically accepted” about a class of products to support the safety or effectiveness of the particular drug for which the applicant is seeking approval. (Note, however, that this does not mean any reference to general information or knowledge (e.g., about disease etiology, support for particular endpoints, methods of analysis) causes the application to be a 505(b)(2) application.)

Types of products for which 505(b)(2) applications are likely to be submitted include: fixed-dose combination drug products (e.g., heart drug and diuretic (hydrochlorothiazide) combinations); OTC monograph deviations (see 21 CFR 330.11); new dosage forms; new indications; and, new salts.

An efficacy supplement can be either a (b)(1) or a (b)(2) regardless of whether the original NDA was a (b)(1) or a (b)(2).

An efficacy supplement is a 505(b)(1) supplement if the supplement contains all of the information needed to support the approval of the change proposed in the supplement. For example, if the supplemental application is for a new indication, the supplement is a 505(b)(1) if:

1. The applicant has conducted its own studies to support the new indication (or otherwise owns or has right of reference to the data/studies),

2. No additional information beyond what is included in the supplement or was embodied in the finding of safety and effectiveness for the original application or previously approved supplements is needed to support the change. For example, this would likely be the case with respect to safety considerations if the dose(s) was/were the same as (or lower than) the original application, and

3. All other “criteria” are met (e.g., the applicant owns or has right of reference to the data relied upon for approval of the supplement, the application does not rely for approval on published literature based on data to which the applicant does not have a right of reference).

An efficacy supplement is a 505(b)(2) supplement if:

1. Approval of the change proposed in the supplemental application would require data beyond that needed to support our previous finding of safety and efficacy in the approval of the
original application (or earlier supplement), and the applicant has not conducted all of its own studies for approval of the change, or obtained a right to reference studies it does not own. For example, if the change were for a new indication AND a higher dose, we would likely require clinical efficacy data and preclinical safety data to approve the higher dose. If the applicant provided the effectiveness data, but had to rely on a different listed drug, or a new aspect of a previously cited listed drug, to support the safety of the new dose, the supplement would be a 505(b)(2),

(2) The applicant relies for approval of the supplement on published literature that is based on data that the applicant does not own or have a right to reference. If published literature is cited in the supplement but is not necessary for approval, the inclusion of such literature will not, in itself, make the supplement a 505(b)(2) supplement, or

(3) The applicant is relying upon any data they do not own or to which they do not have right of reference.

If you have questions about whether an application is a 505(b)(1) or 505(b)(2) application, consult with your ODE’s Office of Regulatory Policy representative.
Appendix B to NDA Regulatory Filing Review
Questions for 505(b)(2) Applications

1. Does the application reference a listed drug (approved drug)? * YES X NO

* PLEASE SEE EXPLANATION ATTACHED

If "No," skip to question 3.

2. Name of listed drug(s) referenced by the applicant (if any) and NDA/ANDA #s: Timolol Maleate *

3. Is this application for a drug that is an "old" antibiotic (as described in the draft guidance implementing the 1997 FDAMA provisions? (Certain antibiotics are not entitled to Hatch-Waxman patent listing and exclusivity benefits.)

   YES □ NO X

If "Yes," skip to question 7.

4. Is this application for a recombinant or biologically-derived product?

   YES □ NO X

If "Yes" contact your ODE’s Office of Regulatory Policy representative.

5. The purpose of the questions below (questions 5 to 6) is to determine if there is an approved drug product that is equivalent or very similar to the product proposed for approval that should be referenced as a listed drug in the pending application.

   (a) Is there a pharmaceutical equivalent(s) to the product proposed in the 505(b)(2) application that is already approved?

      YES □ NO X

      (Pharmaceutical equivalents are drug products in identical dosage forms that: (1) contain identical amounts of the identical active drug ingredient, i.e., the same salt or ester of the same therapeutic moiety, or, in the case of modified release dosage forms that require a reservoir or overage or such forms as prefilled syringes where residual volume may vary, that deliver identical amounts of the active drug ingredient over the identical dosing period; (2) do not necessarily contain the same inactive ingredients; and (3) meet the identical compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times, and/or dissolution rates. (21 CFR 320.1(c))

      If "No," to (a) skip to question 6. Otherwise, answer part (b and (c)).

   (b) Is the pharmaceutical equivalent approved for the same indication for which the 505(b)(2) application is seeking approval?

      YES □ NO □

   (c) Is the approved pharmaceutical equivalent(s) cited as the listed drug(s)?

      YES □ NO □

   If "Yes," (c), list the pharmaceutical equivalent(s) and proceed to question 6.

   If "No," to (c) list the pharmaceutical equivalent and contact your ODE’s Office of Regulatory Policy representative.

   Pharmaceutical equivalent(s):

Version 6/14/2006
6. (a) Is there a pharmaceutical alternative(s) already approved? YES ☐ NO X

(Pharmaceutical alternatives are drug products that contain the identical therapeutic moiety, or its precursor, but not necessarily in the same amount or dosage form or as the same salt or ester. Each such drug product individually meets either the identical or its own respective compendial or other applicable standard of identity, strength, quality, and purity, including potency and, where applicable, content uniformity, disintegration times and/or dissolution rates. (21 CFR 320.1(d)) Different dosage forms and strengths within a product line by a single manufacturer are thus pharmaceutical alternatives, as are extended-release products when compared with immediate- or standard-release formulations of the same active ingredient.)

If “No,” to (a) skip to question 7. Otherwise, answer part (b and (c)).

(b) Is the pharmaceutical alternative approved for the same indication for which the 505(b)(2) application is seeking approval? YES ☐ NO ☐

(c) Is the approved pharmaceutical alternative(s) cited as the listed drug(s)? YES ☐ NO ☐

If “Yes,” to (c), proceed to question 7.

NOTE: If there is more than one pharmaceutical alternative approved, consult your ODE’s Office of Regulatory Policy representative to determine if the appropriate pharmaceutical alternatives are referenced.

If “No,” to (c), list the pharmaceutical alternative(s) and contact your ODE’s Office of Regulatory Policy representative. Proceed to question 7.

Pharmaceutical alternative(s):

7. (a) Does the application rely on published literature necessary to support the proposed approval of the drug product (i.e. is the published literature necessary for the approval)? YES ☐ NO X

If “No,” skip to question 8. Otherwise, answer part (b).

(b) Does any of the published literature cited reference a specific (e.g. brand name) product? Note that if yes, the applicant will be required to submit patent certification for the product, see question 12.

8. Describe the change from the listed drug(s) provided for in this (b)(2) application (for example, “This application provides for a new indication, otitis media” or “This application provides for a change in dosage form, from capsules to solution”). This application provides for a combination product.

9. Is the application for a duplicate of a listed drug and eligible for approval under section 505(j) as an ANDA? (Normally, FDA may refuse-to-file such NDAs (see 21 CFR 314.101(d)(9)).) YES ☐ NO X

10. Is the application for a duplicate of a listed drug whose only difference is that the extent to which the active ingredient(s) is absorbed or otherwise made available to the site of action less than that of the reference listed drug (RLD) (See 314.54(b)(1)). If yes, the application may be refused for filing under 21 CFR 314.101(d)(9)). YES ☐ NO X

Version 6/14/2006
11. Is the application for a duplicate of a listed drug whose only difference is that the rate at which the product's active ingredient(s) is absorbed or made available to the site of action is unintentionally less than that of the RLD (see 21 CFR 314.54(b)(2))? If yes, the application may be refused for filing under 21 CFR 314.101(d)(9).

   YES ☐ NO X

12. Are there certifications for each of the patents listed in the Orange Book for the listed drug(s) referenced by the applicant (see question #2)? (This is different from the patent declaration submitted on form FDA 3542 and 3542a.)

   YES ☐ NO X

13. Which of the following patent certifications does the application contain? (Check all that apply and identify the patents to which each type of certification was made, as appropriate.)

   ☐ Not applicable (e.g., solely based on published literature. See question # 7

   ☐ 21 CFR 314.50(i)(1)(i)(A)(1): The patent information has not been submitted to FDA. (Paragraph I certification)
       Patent number(s):

   ☒ 21 CFR 314.50(i)(1)(i)(A)(2): The patent has expired. (Paragraph II certification)
       Patent number(s):

   ☐ 21 CFR 314.50(i)(1)(i)(A)(3): The date on which the patent will expire. (Paragraph III certification)
       Patent number(s):

   ☐ 21 CFR 314.50(i)(1)(i)(A)(4): The patent is invalid, unenforceable, or will not be infringed by the manufacture, use, or sale of the drug product for which the application is submitted. (Paragraph IV certification)
       Patent number(s):

   NOTE: IF FILED, and if the applicant made a “Paragraph IV” certification [21 CFR 314.50(i)(1)(i)(A)(4)], the applicant must subsequently submit a signed certification stating that the NDA holder and patent owner(s) were notified the NDA was filed [21 CFR 314.52(b)]. The applicant must also submit documentation showing that the NDA holder and patent owner(s) received the notification [21 CFR 314.52(e)]. OND will contact you to verify that this documentation was received.

   ☐ 21 CFR 314.50(i)(3): Statement that applicant has a licensing agreement with the patent owner (must also submit certification under 21 CFR 314.50(i)(1)(i)(A)(4) above).
       Patent number(s):

   ☐ Written statement from patent owner that it consents to an immediate effective date upon approval of the application.
       Patent number(s):


   ☐ 21 CFR 314.50(i)(1)(iii): The patent on the listed drug is a method of use patent and the labeling for the drug product for which the applicant is seeking approval does not include any indications that are covered by the use patent as described in the corresponding use code in the Orange Book. Applicant must provide a statement that the method of use patent does not claim any of the proposed indications. (Section viii statement)
       Patent number(s):

Version 6/14/2006
14. Did the applicant:

- Identify which parts of the application rely on the finding of safety and effectiveness for a listed drug or published literature describing a listed drug or both? For example, pharm/tox section of application relies on finding of preclinical safety for a listed drug.

  YES □ NO X

  If "Yes," what is the listed drug product(s) and which sections of the 505(b)(2) application rely on the finding of safety and effectiveness or on published literature about that listed drug.

  Was this listed drug product(s) referenced by the applicant? (see question # 2)

  YES □ NO □

- Submit a bioavailability/bioequivalence (BA/BE) study comparing the proposed product to the listed drug(s)?

  N/A □ YES □ NO X

15. (a) Is there unexpired exclusivity on this listed drug (for example, 5 year, 3 year, orphan or pediatric exclusivity)? Note: this information is available in the Orange Book.

  YES □ NO X

If "Yes," please list:

<table>
<thead>
<tr>
<th>Application No.</th>
<th>Product No.</th>
<th>Exclusivity Code</th>
<th>Exclusivity Expiration</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
NDA 21-398
Drug: Combigan (brimonidine tartrate/timolol maleate)
Sponsor: Allergan

Allergan submitted NDA 21-398 on September 18, 2001, as a 505 (b)(1) application. It received an approvable (AE) action on June 5, 2002. Allergan submitted a complete response to the AE on June 5, 2002. [During this review cycle it was noted that the submission should be a 505(b)(2) application as it relied on the Agency’s previous findings of safety and efficacy for timolol maleate (NDAs 18-086 and 19-463, both owned by Merck)]. Again, the application received an AE on March 15, 2005. One of the deficiencies cited was the need for patent certification for the primary source data for timolol maleate.

NDA’s 18-086 and 19-463 are owned by Merck and are the reference listed drugs in the Orange Book. Allergan provided a paragraph 2 certification as the Merck patents have expired. Allergan owns NDA 20-613 for .2% brimonidine tartrate although the product has been discontinued.

Allergan submitted a complete response to the second AE on July 29, 2006. The application was submitted as a 505(b)(1). The sponsor has been requested to revise form 356h to reflect that the application is a 505(b)(2). The application included a paragraph 2 certification for timolol maleate (NDAs 18-086 and 19-463).
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/
---------------------
Alison Rodgers
10/3/2006 11:32:08 AM
CSO

Alison Rodgers
10/3/2006 11:36:43 AM
CSO
MEMORANDUM

DATE: August 18, 2006

TO: File

FROM: Alison Rodgers

SUBJECT: NDA 21-398 Resubmission June 29, 2006
NDA 21-398, COMBIGAN (brimonidine tartrate/timolol maleate ophthalmic solution)

The June 29, 2006 resubmission of NDA 21-398 is acceptable from a project management standpoint.
NDA 21-398

Allergan, Inc.
Attention: Lewis Gryziewicz, PharmD
Senior Director, Global Regulatory Affairs
2525 Dupont Drive
P.O. Box 19534
Irvine, CA 92623-9534

Dear Dr. Gryziewicz:

We acknowledge receipt on June 30, 2006, of your June 29, 2006 resubmission to your new drug application for COMBIGAN™ (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5%.

We consider this a complete, class 2 response to our March 14, 2005, action letter. Therefore, the user fee goal date is December 31, 2006.

If you have any questions, call Alison Rodgers, Regulatory Project Manager, at (301) 796-0797.

Sincerely,

(See appended electronic signature page)

Maureen P. Dillon-Parker
Chief, Project Management Staff
Division of Anti-Infective and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Maureen Dillon-Parker
8/2/2006 05:09:49 PM
NDA 21-398; Acknowledgement of resubmission
NDA 21-398

Allergan, Inc.
Attention: Lewis Gryziewicz
Director, Regulatory Affairs
2525 Dupont Drive
P.O. Box 19534
Irvine, CA  92623-9534

Dear Mr. Gryziewicz:

We acknowledge receipt on September 14, 2004, of your September 13, 2004, submission to your new drug application for Combigan (brimonidine tartrate-timolol maleate ophthalmic solution) 0.2%/0.5%.

We consider this a complete, class 2 response to our June 5, 2002, action letter. Therefore, the user fee goal date is March 14, 2005.

If you have any questions, call Michael Puglisi, Project Manager, at (301) 827-2090.

Sincerely,

[See appended electronic signature page]

Carmen DeBellas, R.Ph.
Chief, Project Management Staff
Division of Anti-Inflammatory, Analgesic, and Ophthalmic Drug Products, HFD-550
Office of Drug Evaluation V
Center for Drug Evaluation and Research
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Michael Puglisi
9/29/04 04:14:17 PM
for Carmen DeBellas
MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: May 2, 2002

FROM: Antoine El-Hage, Ph.D, Associate Director
       Good Clinical Practice Branch I & II, HFD-46/47
       Division of Scientific Investigations

SUBJECT: Clinical Inspections Summary – NDA 21-398

TO: Michael Puglisi, Regulatory Project Manager
    Jennifer Harris, M.D., Medical Officer
    Division of Anti-Inflammatory, Analgesic, and Ophthalmologic Drug
    Products, HFD-550

APPLICANT: Allergan

DRUG: Brimonidine/Timolol

CHEMICAL CLASSIFICATION: 4

THERAPEUTIC CLASSIFICATION: Standard Review

INDICATION(S): [Blank]

PDUFA GOAL DATE: July 18, 2002

1. BACKGROUND

Brimonidine tartrate/Timolol ophthalmic solution is a combination product of two
approved single-agent drugs. The sponsor proposes that there will be an additive effect
by simultaneous use of the two agents, which have different mechanisms of action. In
addition, these two drugs are commonly used in conjunction and a combination product
would result in a more convenient dosing regimen.

Protocol 190342-012T was a multicenter, double-masked, randomized, parallel-group
study in subjects with glaucoma or ocular hypertension. The trial compared the
combination test article dosed BIC with brimonidine tartrate dosed TID or timolol dosed
BID. The follow up was up to 1 year.
2. RESULTS (by site):

<table>
<thead>
<tr>
<th>Name</th>
<th>City</th>
<th>State</th>
<th>IN</th>
<th>Assigned</th>
<th>Action Date</th>
<th>Reviewer</th>
<th>Class</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lozier</td>
<td>San Diego</td>
<td>CA</td>
<td>DA</td>
<td>1/9/02</td>
<td>4/25/02</td>
<td>CAC</td>
<td>VAI</td>
</tr>
<tr>
<td>Evans</td>
<td>San Antonio</td>
<td>TX</td>
<td>DA</td>
<td>1/9/02</td>
<td>4/25/02</td>
<td>GRH</td>
<td>VAI</td>
</tr>
<tr>
<td>Wirta</td>
<td>Newport Beach</td>
<td>CA</td>
<td>DA</td>
<td>1/9/02</td>
<td>3/11/02</td>
<td>CAC</td>
<td>VAI</td>
</tr>
</tbody>
</table>

Jeffrey R. Lozier, M.D. – Protocol 190342-012-01

This site enrolled a total of 39 subjects. Thirteen subject’s files were reviewed in depth and the only finding was that one subject had been enrolled prior to receiving medical clearance for a history of cardiovascular disease. There was no indication of underreporting of adverse events. The data appear acceptable.

Richard M. Evans, M.D. – Protocol 190342-012-01

This site enrolled 35 subjects with 30 completing the study. Of the subject records reviewed in depth, minor findings such as 3 subjects receiving the SITA-Fast field test instead of the SITA Standard Test and record keeping deficiencies were found. There was no indication of underreporting of adverse events. The data appear acceptable.

David L. Wirta, M.D. – Protocol 190342-012-01

This site enrolled 42 subjects. Fifteen subject’s files were reviewed in detail. There was only one finding regarding 3 subjects who were not reconsented for the pharmacokinetic arm of the trial. There was no indication of underreporting of adverse events. The data appear acceptable.

3. OVERALL ASSESSMENT OF FINDINGS AND GENERAL RECOMMENDATIONS

No major deficiencies were noted in the three sites inspected that could compromise the integrity of the data. Thus, the data reviewed is acceptable. No subsequent actions or follow up inspections should be undertaken.

CC:
HFD-45/Reading File
HFD-47/El-Hage/Shibuya/Currier
HFD-47/rf/cf
O:\RS\NDA21-377\ClinInspectSumm21-398
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Michele Balser
5/10/02 08:56:30 AM
TECHNICAL
Original was signed by Dr. ElHage on 5/2/02.
MEETING MINUTES

MEETING DATE: 5/30/01  TIME: 2:00pm  LOCATION: CORP. S200A

IND # 58,460  Meeting Request Submission Date – 2/27/01
             Date Sponsor Requested – 5/30/01
             Meeting Packages Submitted – 4/30/01

DRUG: Brimonidine-Timolol Ophthalmic Solution
SPONSOR: Allergan, Inc.
TYPE OF MEETING: Pre-NDA

FDA PARTICIPANTS:

Wiley A. Chambers/ Deputy Division Director
Jonca Bull/ ODE V Deputy Director
William Boyd/ Medical Officer
Joanne Holmes/ Clinical Reviewer
Jennifer Harris/ Medical Officer
Lucious Lim/ Medical Officer
Zhou Chen/ Pharmacologist
Laura Lu/ Statistics Reviewer
Lori Gorski/ Project Manager
Raphael Rodriguez/ Project Manager
Linda Ng/ Chemistry Team Leader
Libaniel Rodriguez/ Chemistry Reviewer
Stan Lin/ Statistics Team Leader
Michael Puglisi/ Project Manager

INDUSTRY PARTICIPANTS:

Melvin Olson/ Biostatistician
Cheryl Larson/ Clinical Research
Scott Whitcup/ Clinical Research
Amy Batoosin/h Clinical Research
Lawrence Lima/ Chemistry & Manufacturing
Peter Kresel/ Senior V.P., Regulatory Affairs
Lewis Gryziewicz/ Director, Regulatory Affairs
Christine Brissey/ Regulatory Affairs
Andrew Acheampong/ Pharmacokinetics
Questions to the Agency

OVERALL

1. Allergan plans to submit the NDA in electronic format in compliance with the FDA Guidance for Industry “Providing Regulatory Submissions in Electronic Format - NDAs”. Does FDA want a paper copy of any or all parts of the NDA?

Agency Response: Yes. The Agency would like but does not require a complete paper archival copy of the NDA submission.

CHEMISTRY

2. Brimonidine Tartrate 0.2% / Timolol 0.5% Ophthalmic Solution will be manufactured using Active Pharmaceutical Ingredients from the approved suppliers in NDA 20-613 Alphagan® (brimonidine tartrate ophthalmic solution) 0.2%, ANDA 74-746, Timolol Maleate Ophthalmic Solution 0.25% and ANDA 74-747, Timolol Maleate Ophthalmic Solution 0.5%. We propose to cross-reference these applications for the API and that no such information is required for the upcoming Brimonidine Tartrate 0.2% / Timolol 0.5% Ophthalmic Solution NDA submission. Please comment.

Agency Response: This proposal is acceptable. LOA to cross-reference these NDAs or DMFs should be submitted. CFN address and contact persons should be submitted for all sites relating to drug substance and drug product.

3. Allergan understands that is currently under review of the FDA's compliance division. Allergan performed stability of Brimonidine Tartrate 0.2% / Timolol 0.5% Ophthalmic Solution using two lots of brimonidine tartrate manufactured by and one by . Allergan proposes to study four batches of Brimonidine Tartrate 0.2% / Timolol 0.5% Ophthalmic Solution for commercial stability, using three lots of brimonidine tartrate from Please comment.

Agency Response: This proposal is acceptable.

4. Allergan analyzed for container/closure extractables in Brimonidine Tartrate 0.2% / Timolol 0.5% Ophthalmic Solution using four methods: 

Allergan commits to a specification for
unspecified/unidentified related substances of NMT = of AGN 190342-LF label claim for the ongoing use of . Allergan proposes that no extractables specification is required for this product. Please comment.

Agency Response: The proposal to set acceptance criteria of NMT = of label claim of AGN 190342-LF for unspecified/unidentified related substances and extractables is acceptable. Establishment of acceptance criteria will be discussed based on the data submitted in the NDA application.

NONCLINICAL

5. As agreed to during the February 8, 1999 end-of-phase 2 meeting, no pharmacology studies were conducted with Brimonidine Tartrate 0.2% / Timolol 0.5% Ophthalmic Solution. No other pharmacology data will be presented. Allergan proposes to include a short introduction justifying the combination of these two ingredients in the Pharmacology sections of the NDA. Please comment.

Agency Response: Acceptable.

6. During the February 8, 1999 end-of-phase 2 meeting it was agreed that no additional nonclinical ADME studies for the combination product are required. However, limited but relevant pharmacokinetic studies were performed to support formulation screening studies and compare ocular distribution of single and combination drug product. Toxicokinetics data were provided for the 6-month ocular Toxicology study in rabbits. The Nonclinical ADME section of the NDA will contain a discussion of these studies only. Please comment.

Agency Response: Acceptable.

7. During the February 8, 1999 end-of-phase 2 meeting, it was agreed that since the ingredients in the formulation have not changed, no additional toxicology studies were needed. Since the combination is intended for global registration, a 6-month ocular study in rabbits was conducted to evaluate the safety of Brimonidine Tartrate 0.2% / Timolol 0.5% Ophthalmic Solution (Allergan study report TX99070). A 1-month ocular study in rabbits was conducted to evaluate the safety of impurity and impurity (Allergan study report TX01001). The two study reports, tabular and written summaries will be provided in the NDA. The Toxicology section of the NDA will consist of an overall summary describing the significant findings in animals for the single components as well as the combination. The previously submitted Brimonidine Tartrate and Brimonidine Purite, NDAs 20-613 and 21-262, respectively, will be cross-referenced. Study reports, tabular and written summaries will not be provided for studies submitted in support of the prior NDAs. Please comment.

Agency Response: Acceptable.
HUMAN PHARMACOKINETICS

8. The Clinical Pharmacokinetics section of the NDA will include a study report for one clinical pharmacokinetic study evaluating systemic exposure of Brimonidine Tartrate 0.2% / Timolol 0.5% Ophthalmic Solution as compared to that of Brimonidine Tartrate 0.2% Ophthalmic Solution and Timolol 0.5% Ophthalmic Solution. In addition, systemic drug exposure of brimonidine and timolol are evaluated in two Phase 3 studies. Please comment.

Agency Response: The proposed studies for the Human Pharmacokinetics section of the NDA is acceptable. This section should also include the assay validation and assay quality control reports for the brimonidine tartrate and timolol.

MICROBIOLOGY

9.

Agency Response: Acceptable.

CLINICAL and STATISTICAL

10. The Statistical Analysis plan submitted to IND 58,460 on October 16, 2000 proposed including Patient Data Listings under Appendix 16.2 of the phase 3 study reports as per ICH E3. Allergan proposed to not include Individual Patient Data Listings (US Archival Listings) under Appendix 16.4 as per ICH E3 in the final study reports or in Section 11, Case Report Tabulations, of the NDA. In place of Appendix 16.4, Allergan will provide FDA with electronic SAS Transport Files for all datasets in Section 11 of the NDA, formatted in compliance with the FDA Guidance “Providing Regulatory Submissions in Electronic Format – NDAs”. Please comment.

Agency Response: Acceptable.

11. The analysis plan for protocols 190342-012T and 013T were revised and issued before the database lock of the first study (-012T) with minor modifications to the original analysis plan reviewed by the Agency. We have included the modified analysis plan, with a summary of the changes as a cover sheet, for review. Please confirm acceptability.

Agency Response: Acceptable.
with glaucoma or ocular hypertension and that the Combination had a safety profile that was superior to Brimonidine and at least as good as Timolol. The analyses presented provide sufficient information for evaluation of the approvability of this product according to the agreed upon criteria. Please comment.

**Agency Response:** The Agency will apply the criteria set forth in 21 CFR §300.50 for fixed combination products. The Agency expects to see replication of study results in a minimum of two separate independent Phase 3 controlled trials. The Phase 3 trials should demonstrate superiority of the fixed combination over each individual components by a clinically significant amount. Differences of 2 mmHg are commonly seen in clinical trials without a change in therapy.

Prepared by: Michael Puglisi/ Project Manager

Concurrence by: Wiley A. Chambers/ Deputy Division Director
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Wiley Chambers
4/19/02 09:16:09 AM